

Financial news for ARIA dated on 2017-04-12: Earnings Scheduled For April 12, 2017

Financial news for ARIA dated on 2017-02-16: BZ NOTE: Takeda Has Acquired ARIAD, Will No Longer Trade

Financial news for ARIA dated on 2017-02-16: ARIAD Pharma Shares Halted for Added Info

Financial news for ARIA dated on 2017-02-06: ARIAD Pharma Submits Marking Authorization Application to European Medicines Agency for Brigatinib

Financial news for ARIA dated on 2017-01-31: Watch These 10 Huge Put Purchases In Tuesday Trade

Financial news for ARIA dated on 2017-01-30: Benzinga's Option Alert Recap From January 30

Financial news for ARIA dated on 2017-01-30: Option Alert: Ariad Feb 16.0 Puts Sweep: 524 @ ASK \$0.05: 13k traded vs 60 OI: Earnings 2/23 Before Open (est) \$23.66 Ref

Financial news for ARIA dated on 2017-01-27: Watch These 10 Huge Put Purchases In Friday Trade

Financial news for ARIA dated on 2017-01-26: Option Alert: Ariad Feb 24th 16.0 Puts: 15000 @ ASK \$0.05: 15k traded vs 10k OI: Earnings 2/23 Before Open (est) \$23.67 Ref

Financial news for ARIA dated on 2017-01-26: Option Alert: Ariad Feb 24th 16.0 Puts: 15000 @ ASK \$0.05: 15k traded vs 10k OI: Earnings 2/23 Before Open (est) \$23.67 Ref

Financial news for ARIA dated on 2017-01-25: Takeda's Speculative Interest In Synergy Soothes Stomach Pains; Canaccord Says Buy

Financial news for ARIA dated on 2017-01-11: ARIAD Pharmaceuticals Shares Quiet Following Earlier Downgrade by SunTrust

Financial news for ARIA dated on 2017-01-10: Benzinga's Top Upgrades, Downgrades For January 10, 2017

Financial news for ARIA dated on 2017-01-10: Wall Street's M&A Chatter From January 9

Financial news for ARIA dated on 2017-01-10: Barclays Upgrades ARIAD Pharmaceuticals to Equal-Weight, Announces \$24.00 Target

Financial news for ARIA dated on 2017-01-10: Jefferies Downgrades ARIAD Pharmaceuticals to Hold

Financial news for ARIA dated on 2017-01-09: Mid-Afternoon Market Update: Ariad Pharmaceuticals Surges On Acquisition News; Stage Stores Shares Slide

Financial news for ARIA dated on 2017-01-09: Mid-Day Market Update: Acuity Brands Drops On Disappointing Results; Surgical Care Affiliates Shares Surge

Financial news for ARIA dated on 2017-01-09: Mid-Morning Market Update: Markets Mostly Lower; Global Payments Earnings Beat Views

Financial news for ARIA dated on 2017-01-09: Takeda to Acquire ARIAD Pharmaceuticals, Inc. For \$24/Share Cash Or EV Of ~\$5.2B

Financial news for ARIA dated on 2017-01-09: ARIAD Shares Halted News Pending

Financial news for ARIA dated on 2016-12-13: 10 Stocks With Lowest Close In Three Weeks

Financial news for ARIA dated on 2016-12-07: Mid-Day Market Update: Dave & Buster's Climbs On Upbeat Results; Sigma Designs Shares Slide

Financial news for ARIA dated on 2016-12-07: Option Alert: ARIA Dec16 13.0 Calls: 500 @ ASK \$0.35: 506 traded vs 93 OI: Earnings 2/23 Before Open (est) \$12.53 Ref

Financial news for ARIA dated on 2016-12-07: Bernie Sanders' 'Trump Proposal' To Lower Drug Prices Blocked By Senate Republicans

Financial news for ARIA dated on 2016-12-07: Ariad Reports Brigatinib Demonstrated 15.6 Month Systemic Median Progression-free Survival in Alta Study

Financial news for ARIA dated on 2016-12-06: ARIAD Announces Iclusig Data Presentation at ASH 2016

Financial news for ARIA dated on 2016-12-05: ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer

Financial news for ARIA dated on 2016-11-29: ARIAD Announces FDA Full Approval and Label Update for Iclusig Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial

Financial news for ARIA dated on 2016-11-25: Watch These Huge Put Purchases In Friday Trade

Financial news for ARIA dated on 2016-11-23: Option Alert: ARIA Jan. \$14 Puts Sweep at the Bid: Volume of 1,000 at \$1.551 vs Open Interest 740

Financial news for ARIA dated on 2016-11-17: Technical Alert: Ariad Pharmaceuticals Nears Major Resistnce

Financial news for ARIA dated on 2016-11-16: Jefferies London Healthcare Conference Taking Place Today

Financial news for ARIA dated on 2016-11-14: Ariad Spikes to High of \$12.92 on Volume

Financial news for ARIA dated on 2016-11-14: Watch These 7 Huge Call Purchases In Monday Trade

Financial news for ARIA dated on 2016-11-11: Option Alert: ARIA Dec16 14.0 Calls Sweep: 1000 @ ASK \$0.45: 1006 traded vs 43 OI: Earnings 2/23 Before Open (est) \$11.99 Ref

Financial news for ARIA dated on 2016-11-09: Mid-Afternoon Market Update: Dow Climbs 250 Points; Impax Labs Shares Down Following Q3 Results

Financial news for ARIA dated on 2016-11-09: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for ARIA dated on 2016-11-09: Mid-Day Market Update: Dow Surges Over 100 Points; Coty Shares Slide

Financial news for ARIA dated on 2016-11-09: Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%

Financial news for ARIA dated on 2016-11-09: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARIA dated on 2016-11-09: ARIAD Announces Phase 1/2 Trial Data on Investigational Drug Brigatinib Published in The Lancet Oncology

Financial news for ARIA dated on 2016-11-07: ARIAD Reaffirms FY16 Global Iclusig Net Product and Royalty Rev. Of \$170-\$180M

Financial news for ARIA dated on 2016-11-07: ARIAD Reports Q3 EPS \$(0.14) vs. Est. \$(0.19), Rev. \$46.016M vs. Est. \$42.93M

Financial news for ARIA dated on 2016-11-03: Benzinga's Top Initiations

Financial news for ARIA dated on 2016-11-03: Deutsche Bank Initiates Coverage On ARIAD Pharmaceuticals, Inc. - Common Stock at Hold, Announces \$9.50

Financial news for ARIA dated on 2016-10-31: ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib, Brigatinib Granted Priority Review, with a PDUFA Date of April 29, 2017

Financial news for ARIA dated on 2016-10-26: ARIAD Reports Publication of the Preclinical Profile of Brigatinib in the Journal Clinical Cancer Research

Financial news for ARIA dated on 2016-10-25: Option Alert: ARIA Fri 10/28 10.0 Calls (Wkly): 557 @ ASK \$0.30: 1221 traded vs 390 OI: Earnings 11/3 Before Market (unconf) \$9.56 Ref

Financial news for ARIA dated on 2016-10-25: Option Alert: ARIA Fri 10/28 10.0 Calls (Wkly) Sweep: 500 @ ASK \$0.30: 664 traded vs 390 OI: Earnings 11/3 Before Market (unconf) \$9.45 Ref

Financial news for ARIA dated on 2016-10-25: JMP Securities Downgrades Ariad, Cites Limited Near-Term Upside In Light Of Prescription Trends

Financial news for ARIA dated on 2016-10-25: The Market In 5 Minutes: UA, GM, P&G

Earnings On The Street's Mind

Financial news for ARIA dated on 2016-10-25: Benzinga's Top Downgrades

Financial news for ARIA dated on 2016-10-25: JMP Securities Downgrades ARIAD Pharmaceuticals, Inc. - Common Stock to Market Perform

Financial news for ARIA dated on 2016-10-24: Mid-Afternoon Market Update: ACCO Brands Gains On Earnings Beat; Boise Cascade Shares Down

Financial news for ARIA dated on 2016-10-24: 12 Biggest Mid-Day Losers For Monday

Financial news for ARIA dated on 2016-10-24: Ariad Lower For Seventh Day In A Row Following JPMorgan Downgrade

Financial news for ARIA dated on 2016-10-24: Mid-Morning Market Update: Markets Open Higher; AT&T to Acquire Time Warner For \$85.4B

Financial news for ARIA dated on 2016-10-24: The Market In 5 Minutes: Industry-Changing M&A In Media, Aerospace, And Financial Services

Financial news for ARIA dated on 2016-10-24: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for ARIA dated on 2016-10-24: JP Morgan Downgrades ARIAD Pharmaceuticals, Inc. - Common Stock to Underweight

Financial news for ARIA dated on 2016-10-21: Ariad Pharmaceuticals Responds To Congressional Letter

Financial news for ARIA dated on 2016-10-21: Watch These 4 Huge Put Purchases In Friday Trade

Financial news for ARIA dated on 2016-10-20: TheStreet's Adam Feuerstein Tweets '\$ARIA has no right to expect \$1.4B in cumulative losses to be recovered. Arrogance. They should say, we're cutting the price.'

Financial news for ARIA dated on 2016-10-20: Adam Feuerstein @adamfeuerstein Tweet: @pemulisking \$ARIA has no right to expect \$1.4B in cumulative losses to be recovered. Arrogance. They should say, we're cutting the price.

Financial news for ARIA dated on 2016-10-20: Ariad Pharmaceuticals Acknowledges Receipt Of Congressional Letter

Financial news for ARIA dated on 2016-10-20: Bernie Sanders And Rep. Cummings To Ariad: Explain Why Iclusig Now Costs \$199,000 A Year

Financial news for ARIA dated on 2016-10-20: Option Alert: ARIA Oct \$10.5 Put Sweep; 800 vs 425 OI @Ask @\$0.55

Financial news for ARIA dated on 2016-10-20: UPDATE: Full Sanders Letter To ARIAD Pharmaceuticals CEO

Financial news for ARIA dated on 2016-10-20: Ariad Shares Sell off to Low of \$10.52 Following Report of Sanders, Cummings Letter to CEO

Financial news for ARIA dated on 2016-10-20: Senators Sanders & Cummings In Letter To Ariad Pharma, Says Interested In Learning More About Impact That Escalating Price, Restrictions On Iclusig Availability Have Had

Financial news for ARIA dated on 2016-10-17: Ariad -13.54% Premarket @\$11.30 Following Friday's Bernie Sanders Tweet Admonishing Co on Pricing of Leukemia Treatment

Financial news for ARIA dated on 2016-10-14: Mid-Afternoon Market Update: Enzo Biochem Rises Following Q4 Results; Natural Health Trends Shares Decline

Financial news for ARIA dated on 2016-10-14: Ariad Pharma Shares Tick Lower on Heavy Volume; Traders Circulating Hour-Old Tweet from Bernie Sanders on Pricing of Leukemia Drug

Financial news for ARIA dated on 2016-10-14: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for ARIA dated on 2016-10-10: The ESMO Conference Proves Its Ability To Move Stocks

Financial news for ARIA dated on 2016-10-10: ARIAD Reports Data On Phase 1/2 Trial On Investigational Drug Brigatinib

Financial news for ARIA dated on 2016-10-07: Watch These 5 Huge Put Purchases In Friday Trade

Financial news for ARIA dated on 2016-10-06: Option Alert: ARIA Jan17 12.0 Puts Sweep: 833 @ ASK \$1.30: 4001 traded vs 1431 OI: Earnings 11/1 \$13.29 Ref

Financial news for ARIA dated on 2016-10-06: Adam F/Street.com Article 'How Ariad Pharma Used a Safety Problem to Jack Up the Price of a Cancer Drug'

Financial news for ARIA dated on 2016-10-06: Ariad Pharma Spikes to High of \$14.15 on Volume

Financial news for ARIA dated on 2016-10-05: Ariad Pharmaceuticals Raises Cancer Drug Price For The 4th Time This Year

Financial news for ARIA dated on 2016-10-05: Ariad Pharmaceuticals Expected To See Clinical Catalysts

Financial news for ARIA dated on 2016-10-05: SunTrust Note From Earlier This Morning Highlighting Multiple ARIAD Price Increases For Iclusig In 2016, Being Mentioned On Social Media By Many Notable Biotech Pundits

Financial news for ARIA dated on 2016-10-04: SunTrust Robinson Humphrey Initiates Coverage on ARIAD Pharmaceuticals at Buy, Announces \$22.00 PT

Financial news for ARIA dated on 2016-09-28: ARIAD Announces Regulatory Approval for Iclusig in Japan, Triggers \$10M Milestone Payment To ARIAD

Financial news for ARIA dated on 2016-09-27: Stocks Hitting 52-Week Highs

Financial news for ARIA dated on 2016-09-27: Stocks Hitting 52-Week Highs

Financial news for ARIA dated on 2016-09-26: Incyte Could Be A Takeover Target, Argus Lifts Price Target To \$98

Financial news for ARIA dated on 2016-09-26: Option Alert: ARIA 9/30 14.0 Calls (Wkly): 500 @ ASK \$0.25: 570 traded vs 127 OI: Earnings 11/1 \$13.77 Ref >> Option Alert: MSFT Jan17 52.5 Puts: 2000 @ ASK \$1.23: 2002 traded vs 29k OI: Earnings 10/20 After Close \$56.95 Ref

Financial news for ARIA dated on 2016-09-26: Ariad's Recent Run Has Stock At Highest Levels Since October 2013

Financial news for ARIA dated on 2016-09-26: Leerink Expects Ariad Pharmaceuticals To Outperform

Financial news for ARIA dated on 2016-09-26: Benzinga's Top Initiations

Financial news for ARIA dated on 2016-09-26: Leerink Swann Initiates Coverage on ARIAD Pharmaceuticals at Outperform

Financial news for ARIA dated on 2016-09-21: Ariad Pharma Shares Up 4.3% in Pre-Market Action Wed., Up 24% Since Beginning of Last Week; RBC Analyst Recently Highlighted Co. as a Top Takeover Target in the Biotech Group

Financial news for ARIA dated on 2016-09-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARIA dated on 2016-09-20: Technical Alert: Ariad Pharmaceuticals Reaches Highest Level October 2013

Financial news for ARIA dated on 2016-09-12: Watch These 7 Huge Call Purchases In Monday Trade

Financial news for ARIA dated on 2016-09-09: Option Alert: ARIA Sep16 11.0 Calls Sweep: 2478 @ ASK \$0.15: 2498 traded vs 649 OI: Earnings 11/1 \$10.20 Ref

Financial news for ARIA dated on 2016-08-30: Aria Pharma Completes Rolling Submission of NDA for Brigatnib

Financial news for ARIA dated on 2016-08-12: Option Alert: ARIA Aug16 11.5 Calls Sweep: 500 @ ASK \$0.20: 500 traded vs 2116 OI: \$10.65 Ref

Financial news for ARIA dated on 2016-08-09: Watch These 7 Huge Call Purchases In Tuesday Trade

Financial news for ARIA dated on 2016-08-08: Option Alert: ARIA Aug16 11.0 Calls Sweep: 881 @ ASK \$0.20: 2070 traded vs 2575 OI: \$9.98 Ref

Financial news for ARIA dated on 2016-08-08: Option Alert: ARIA Aug16 11.5 Calls Sweep: 2000 @ ASK \$0.10: 2000 traded vs 0 OI: \$9.96 Ref

Financial news for ARIA dated on 2016-07-28: Technical Alert: Finding Resistance In Ariad Pharmaceuticlas After Q2 Report

Financial news for ARIA dated on 2016-07-28: ARIAD Reports Q2 EPS \$0.59 Does Not Compare To \$(0.11), Rev. \$65.3M vs. Est. \$60.6M

Financial news for ARIA dated on 2016-06-22: Option Alert: ARIA Fri 6/24 8.0 Calls (Wkly) Sweep: 1000 @ ASK \$0.10: 1040 traded vs 354 OI: Earnings 8/3 \$7.40 Ref

Financial news for ARIA dated on 2016-06-17: Ariad Shares Ticking Higher; Traders Attributing to Positive Comments from RBC

Financial news for ARIA dated on 2016-06-17: Mid-Afternoon Market Update: Crude Oil Up Over 3%; Lumber Liquidators Shares Spike Higher

Financial news for ARIA dated on 2016-06-17: 5 Biggest Mid-Day Losers For Friday

Financial news for ARIA dated on 2016-06-17: Ariad Sells off to Low of \$7.64; Co Reaffirmed 2016 Financial Guidance

Financial news for ARIA dated on 2016-06-17: ARIAD Reaffirms FY16 Product & Royalty Rev. \$170-\$180M, Sees Expected 25% Reduction In SG&A Expense In FY16

Financial news for ARIA dated on 2016-06-17: ARIAD Initiates Submission Of NDA For Brigatinib Ahead Of Plan

Financial news for ARIA dated on 2016-06-17: ARIAD Reports Distribution Agreements for Iclusig in Latin America and the Middle East/North Africa, Will Receive Upfront & Potential Regulatory Milestone Payments Of \$15M

Financial news for ARIA dated on 2016-06-17: ARIAD Reports Initiated Submission of NDA for Briagtinib Ahead of Plan

Financial news for ARIA dated on 2016-06-13: Ariad Reveals Ponatinib's Long-Term Safety And Efficacy Data From Stage 2 Clinical Study

Financial news for ARIA dated on 2016-06-13: ARIAD Reports Long-Term Safety, Efficacy Data of Ponatinib from Phase 2 Pace Trial: 82% of CP-CML Patients Who Achieved MCyR Estimated to Remain in MCyR at Four Years

Financial news for ARIA dated on 2016-06-10: Watch These 7 Huge Call Purchases In Friday Trade

Financial news for ARIA dated on 2016-06-09: Option Alert: ARIA Jan17 10.0 Calls Sweep: 711 @ ASK \$1.20: 711 traded vs 4390 OI: \$8.84 Ref

Financial news for ARIA dated on 2016-06-06: ARIAD Pharma Reports Brigatinib Shows 54% Confirmed Objective Response Rate, 12.9-Month Median Progression Free Survival

Financial news for ARIA dated on 2016-06-04: ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients at #ASCO16

Financial news for ARIA dated on 2016-06-04: ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations at #ASCO16

Financial news for ARIA dated on 2016-06-03: 12 Stocks Moving In Friday's Pre-Market Session

Financial news for ARIA dated on 2016-06-03: Premarket Gainers: Talen Energy + 15.58%; Violin Memory +13.07%, Ambarella +10.40%; Broadcom +7.8%, Ariad +5.27%

Financial news for ARIA dated on 2016-05-31: ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788

Financial news for ARIA dated on 2016-05-27: Option Alert: ARIA Jul16 10.0 Calls Sweep: 1011 @ ASK \$0.20: 7161 traded vs 0 OI: \$8.11 Ref

Financial news for ARIA dated on 2016-05-24: Jeffires' Eun Yang Commented on Ariad Pharma's Investor Event With Management: 'Steady Upside Likely to Continue'

Financial news for ARIA dated on 2016-05-23: Option Alert: ARIA Fri 5/27 8.0 Calls (Wkly) Sweep: 638 @ ASK \$0.25: 1178 traded vs 74 OI: \$8.09 Ref

Financial news for ARIA dated on 2016-05-17: Option Alert: ARIA May16 7.5 Puts Sweep: 1000 @ ASK \$0.20: 1000 traded vs 13 OI: \$7.78 Ref

Financial news for ARIA dated on 2016-05-10: ARIAD Cuts FY16 Iclusig Sales Outlook from \$190M-\$200M to \$170M-\$180M vs \$198M Est.

Financial news for ARIA dated on 2016-05-10: ARIAD Pharma Reports Q1 Adj. EPS \$(0.23), Inline, Sales \$33.6M

Financial news for ARIA dated on 2016-05-09: Incyte to Acquire ARIAD's European Operations for \$140M

Financial news for ARIA dated on 2016-05-05: Cowen & Company Upgrades ARIAD Pharmaceuticals to Outperform

Financial news for ARIA dated on 2016-04-19: BZ NOTE: Sarissa Capital is Currently Largest Holder in ARIAD Pharma, Owns ~15.6% Stake

Financial news for ARIA dated on 2016-04-19: Hearing Sarissa Capital Alexander Denner, During 'Activist Lightning Round' at 13D Monitor Conference, Has Given ARIAD as Investment Idea

Financial news for ARIA dated on 2016-04-19: ARIAD Reports AP32788 Preclinical Studies At AACR Conf., Will Enroll Patients Q2 2016

Financial news for ARIA dated on 2016-04-15: 10 Stocks Moving In Friday's Pre-Market Session

Financial news for ARIA dated on 2016-04-15: UPDATE: Ariad Says Serious Adverse Events Were Dyspnea (7%), Pneumonia (6%), Hypoxia (5%), Neoplasm Progression (5%), Pulmonary Embolism (3%), Malignant Pericardial Effusion (2%), Pyrexia (2%)

Financial news for ARIA dated on 2016-04-15: UPDATE: Ariad Says Median PFS was Not Yet Reached in ALK+ NSCLC Patients who were Crizotinib-naïve (n=8)

Financial news for ARIA dated on 2016-04-15: ARIAD Gives Updated 1/2 Clinical Data On Brigatinib, Reports An Overall Survival Rate In 100% crizotinib-naïve patients, and 81% in patients with prior crizotinib treatment

Financial news for ARIA dated on 2016-04-11: ARIAD Reports Start of Randomized, First-Line Phase 3 Trial of Brigatinib in Treatment of ALK-Positive Non-Small Cell Lung Cancer

Financial news for ARIA dated on 2016-03-29: UPDATE: ARIAD Pharma Will Cut ~25% of HQ Positions, or ~90 Jobs in US, Europe

Financial news for ARIA dated on 2016-03-29: ARIAD Reports Workforce Reduction

Financial news for ARIA dated on 2016-03-11: ARIAD Names Manmeet Soni CFO

Financial news for ARIA dated on 2016-02-25: ARIAD Should Be Valued At \$10/Share In A Takeout, Says Shares May Trade Up On Expected Announcement Of Cost Cutting Efforts In Q2 Strategic Update

Financial news for ARIA dated on 2016-02-25: Hearing RBC Says Ariad Takeover Candidate

Financial news for ARIA dated on 2016-02-23: ARIAD Reports Q4 EPS \$(0.32), Inline, Sales \$33.3M vs \$41.4M Est.

Financial news for ARIA dated on 2016-02-23: ARIAD Sees Iclusig Net Rev. For FY16 Between \$190-\$200M

Financial news for ARIA dated on 2016-02-03: CEO Panayiotopoulos Buys 61,099 Shares Of Ariad Pharmaceuticals @\$4.91/Share -Form 4

Financial news for ARIA dated on 2016-02-03: The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors

Financial news for ARIA dated on 2016-02-01: Ariad Announces FDA Has Given Clearance To Begin Clinical Development Trial

Financial news for ARIA dated on 2016-02-01: ARIAD Reports FDA Clearance to Begin Clinical Development of AP32788

Financial news for ARIA dated on 2016-01-19: Benzinga's Top Initiations

Financial news for ARIA dated on 2016-01-19: Barclays Initiates Coverage on ARIAD

Pharmaceuticals at Underweight, Announces \$6.00 PT

Financial news for ARIA dated on 2016-01-10: ARIAD Elects of Alex Denner as Chairman of the Board of Directors

Financial news for ARIA dated on 2016-01-08: ARIAD, Otsuka Submit New Drug Application in Japan for Ponatinib

Financial news for ARIA dated on 2015-12-18: ARIAD Names Paris Panayiotopoulos CEO

Financial news for ARIA dated on 2015-12-11: Mid-Morning Market Update: Markets Open Lower; Dow Chemical And DuPont Announce Merger

Financial news for ARIA dated on 2015-12-11: Benzinga's Top #PreMarket Losers

Financial news for ARIA dated on 2015-12-11: UPDATE: ARIAD Originally Had Rev. Guidance Of \$130-\$140M For Iclusig, Now Expects \$110-\$115M

Financial news for ARIA dated on 2015-12-11: Ariad Pharma Expects Global Product Revenue From \$110M to \$115M

Financial news for ARIA dated on 2015-12-07: Option Alert: ARIA Jan16 5.0 Calls Sweep: 5038 @ ASK \$1.20: 5038 traded vs 2710 OI: \$5.82 Ref

Financial news for ARIA dated on 2015-12-07: ARIAD Reports OPTIC-2L Initiation Of OPTIC-2L Random Phase 3 Trial Of ponatinib vs. nilotinib

Financial news for ARIA dated on 2015-11-04: Option Alert: \$ARIA Dec \$9 Call Sweep; 2000 Contract Trade at Ask @\$0.30

Financial news for ARIA dated on 2015-11-03: ARIAD Reports Q3 EPS \$(0.29) vs. Est. \$(0.23), Rev. \$29.07M vs. Est. \$46.09

Financial news for ARIA dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for ARIA dated on 2015-09-17: Option Alert: \$ARIA Jan \$10 Call Sweep: 1212 Contracts @Ask @\$0.75, Now \$8.14

Financial news for ARIA dated on 2015-09-15: Benzinga's Top #PreMarket Losers

Financial news for ARIA dated on 2015-09-15: ARIAD Reports Full Enrollment in Phase 2 ALTA Trial of Brigatinib

Financial news for ARIA dated on 2015-09-10: Aria Pharma 13G Shows Holder Putnam Investments Holds 10.1% Stake

Financial news for ARIA dated on 2015-09-04: Mid-Morning Market Update: Markets Open Lower; BlackBerry To Acquire Good Technology For \$425M

Financial news for ARIA dated on 2015-09-03: Ariad Pharmaceutical VP Cantor Sells 2,696 Shares @\$9.11/Share -Form 4

Financial news for ARIA dated on 2015-09-02: Bloomberg TV: Baxalta Ends Bid For Ariad

Financial news for ARIA dated on 2015-08-31: Mid-Afternoon Market Update: NASDAQ Down 1.3%; Medicines Company Shares Gain Following Announcement Of Positive ALN-PCSSc Study Results

Financial news for ARIA dated on 2015-08-31: Mid-Day Market Update: Crude Oil Surges 5.5%; ConforMIS Shares Tumble

Financial news for ARIA dated on 2015-08-31: Morning Market Losers

Financial news for ARIA dated on 2015-08-31: Benzinga's Top #PreMarket Losers

Financial news for ARIA dated on 2015-08-31: Must Watch Stocks for August 31, 2015

Financial news for ARIA dated on 2015-08-30: Benzinga's Weekend M&A Chatter

Financial news for ARIA dated on 2015-08-28: Ariad Pharma Trading Up ~39% At \$9.751 On The Day, Jumped From News Reported By CNBC That Baxalta Approached Company A Month Ago And Ariad Balked On Initial Offer

Financial news for ARIA dated on 2015-08-28: Ariad Spiking Higher Again on Rumor of Baxalta Offer

Financial news for ARIA dated on 2015-08-28: Adam Feuerstein @adamfeuerstein Tweet: (\$ARIA) Probably related to report \$BXLTL looking for hem/onc acquisition in \$2B range.

Financial news for ARIA dated on 2015-08-28: Option Alert: \$ARIA Sep 4 \$7 Call Sweep; 1260 Contracts @Ask @\$0.65; Now \$7.40

Financial news for ARIA dated on 2015-08-18: Mid-Day Market Update: Tuesday's Top Shorted Stocks

Financial news for ARIA dated on 2015-08-10: ARIAD Reports First Patient Treated in Phase 2 Dose-Ranging Optic Trial of Iclusig (Ponatinib)

Financial news for ARIA dated on 2015-08-05: Ariad Pharma Reports Q2 Loss \$0.33 Vs Est Loss \$0.27, Revs \$29.2M vs Est \$33.24M

Financial news for ARIA dated on 2015-07-31: Option Alert: Ariad Aug \$9.00 Call Sweep; 1900 Contracts @Ask @\$0.20; Now \$8.08

Financial news for ARIA dated on 2015-07-29: ARIAD to Receive up to \$200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma

Financial news for ARIA dated on 2015-06-15: JMP Sees A 'Negative Market Tone' In Biotechnology

Financial news for ARIA dated on 2015-06-12: ARIAD Reports Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

Financial news for ARIA dated on 2015-06-10: ARIAD, Paladin Report Commercial Distribution Agreement For Iclusig In Canada

Financial news for ARIA dated on 2015-06-03: 3 Stocks That Made A Big Impact At ASCO

Financial news for ARIA dated on 2015-06-03: What's Happening At The ASCO Conference?

Financial news for ARIA dated on 2015-06-01: ARIAD Showcases Updated Clinical Data on brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer at the 2015 ASCO Meeting

Financial news for ARIA dated on 2015-05-31: ARIAD Announces Long-Term Safety, Efficacy Data of Ponatinib in Chronic-Phase CML from Phase 1 Clinical Trial

Financial news for ARIA dated on 2015-05-22: ARIAD Reports Data Presentations at the European Hematology Association Congress

Financial news for ARIA dated on 2015-05-14: Stifel Talks 5 Biotech Stocks

Financial news for ARIA dated on 2015-05-07: Ariad Pharmaceuticals Says On Track To Achieve Full Enrollment of ~220 Patients in Alta Trial in Q3 of 2015

Financial news for ARIA dated on 2015-05-07: ARIAD Reports Q1 Loss of \$0.28/Share vs Loss of \$0.27/Share Est., Sales \$24M vs \$26.9M Est.

Financial news for ARIA dated on 2015-05-06: ARIAD Reports Commercial Distribution Deal for ICLUSIG

Financial news for ARIA dated on 2015-05-01: Shares of Ariad Pharmaceuticals Rise 2% Premarket; May be Attributed to Stifel Note Mentioning Co as Potential Takeover Target

Financial news for ARIA dated on 2015-04-29: UPDATE: Ariad 'Far Along' In Partnership Talks For Brigatinib

Financial news for ARIA dated on 2015-04-29: Ariad Open to strategic Alternatives According to Departing CEO

Financial news for ARIA dated on 2015-04-29: Morning Market Gainers

Financial news for ARIA dated on 2015-04-29: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2015-04-29: ARIAD Reports Settlement Deal with Sarissa Capital Mgmt; Announces Founder, Chair, CEO Harvey Berger to Retire

Financial news for ARIA dated on 2015-04-22: ARIAD Announces Issuance of Key U.S. Patent on Brigatinib

Financial news for ARIA dated on 2015-04-21: ARIAD Reports Results of Preclinical Studies on Brigatinib at the American Association for Cancer Research Annual Meeting

Financial news for ARIA dated on 2015-04-18: These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals

Financial news for ARIA dated on 2015-04-17: Option Alert: Ariad Apr 24 \$9.5 Call;

1400 Contract Trade at Ask @\$0.20

Financial news for ARIA dated on 2015-04-17: ARIAD Offers Updated Clinical Data for Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer

Financial news for ARIA dated on 2015-04-13: Option Alert: Ariad Apr \$9 Call; 1160 Contract Trade at Ask @\$0.15

Financial news for ARIA dated on 2015-04-06: ARIAD Reports Approval of ICLUSIG in Canada

Financial news for ARIA dated on 2015-03-25: ARIAD Reports Dismissal of Holders Class Action Suit in Federal District Court

Financial news for ARIA dated on 2015-03-24: ARIAD and Medison Pharma Announce Approval of Iclusig (Ponatinib) in Israel

Financial news for ARIA dated on 2015-03-16: Option Alert: Ariad Mar \$8.5 Call; 1990 Contract Trade at Ask @\$0.35

Financial news for ARIA dated on 2015-03-10: ARIAD Reports Dismissal of Holder Derivative Suit

Financial news for ARIA dated on 2015-02-21: JMP Feeling Mostly Good On 4 Drug, Healthcare Stocks

Financial news for ARIA dated on 2015-02-20: Technical Breakout In Ariad Pharmaceuticals

Financial news for ARIA dated on 2015-02-20: Sarissa Capital Management Says it has been in Negotiations With Certain Ariad Pharmaceuticals Board Members in Attempt to Avoid Potential Proxy Contest by Sarissa

Financial news for ARIA dated on 2015-02-19: UPDATE: CEO ARIAD Projects Profitability in 2018

Financial news for ARIA dated on 2015-02-19: ARIAD Releases 2015 Guidance, Expect Rev. \$130M-\$140M

Financial news for ARIA dated on 2015-02-19: ARIAD Reports Q4 Loss of \$0.03/Share vs Loss of \$0.08/Share Est.

Financial news for ARIA dated on 2015-02-19: Earnings Scheduled For February 19, 2015

Financial news for ARIA dated on 2015-02-14: CNBC's Stock Pops & Drops From February 13

Financial news for ARIA dated on 2015-02-06: Should Ligand Pharmaceuticals Worry Investors?

Financial news for ARIA dated on 2015-01-26: Ariad Pharmaceuticals Chairman Berger Buys 25,000 Shares @\$6.17/Share -Form 4

Financial news for ARIA dated on 2015-01-20: Tuesday's Morning Movers: FXCM Takes Another Big Drop

Financial news for ARIA dated on 2015-01-20: ARIAD Reports Final Decision from European Commission Endorsing Iclusig's Approved Indications Throughout Europe

Financial news for ARIA dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for ARIA dated on 2015-01-13: UPDATE: ARIAD 2015 Objectives and 2014 Preliminary Results

Financial news for ARIA dated on 2015-01-13: ARIAD Offers Key Strategic Objectives for '15: Reports Prelim. '14 Iclusig Sales \$55M; Expecting to Secure Partnership for Brigatinib in '15

Financial news for ARIA dated on 2015-01-11: Credit Suisse's 4 Healthcare Stocks To Avoid

Financial news for ARIA dated on 2015-01-06: ARIAD Reports Phase 2 Dose-Ranging Trial of Iclusig to Begin by Mid-2015: Randomized Global Trial Will Evaluate Safety, Efficacy at Three Starting Doses

Financial news for ARIA dated on 2015-01-05: Benzinga's Top #PreMarket Losers

Financial news for ARIA dated on 2014-12-30: UPDATE: Bellicum Paid \$20M, \$15M

Payments Owed to ARIAD on Dec. 29th

Financial news for ARIA dated on 2014-12-30: 8-K from ARIAD Pharma Shows Amended License Deal with Bellicum

Financial news for ARIA dated on 2014-12-30: Tuesday's #PreMarket Movers: Neuroderm, Microsoft, Medbox, Civeo And More

Financial news for ARIA dated on 2014-12-30: UPDATE: ARIAD Deal with Angelini Pharma; Co. Will Grant Exclusive Rights, Angelini to Provide Substantial Share of Product Sales

Financial news for ARIA dated on 2014-12-30: ARIAD Reports Commercialization Deal for Iclusig in Seven Countries

Financial news for ARIA dated on 2014-12-23: Tuesday's #PreMarket Movers: NQ Mobile, Cytokinetics, Walgreen And More

Financial news for ARIA dated on 2014-12-23: ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other

Financial news for ARIA dated on 2014-12-16: Option Alert: Ariad Jan \$8 Call; 1,000 Contract Trade at Ask @\$0.30; Currently \$6.25

Financial news for ARIA dated on 2014-12-11: Mid-Afternoon Market Update: Oxford Industries Drops On Downbeat Results; Office Depot Shares Spike Higher

Financial news for ARIA dated on 2014-12-11: Mid-Day Market Update: Dow Jumps Over 200 Points; Staples Shares Surge On Confirmation Of Stake By Starboard Value

Financial news for ARIA dated on 2014-12-11: Mid-Morning Market Update: Markets Surge; Lululemon Profit Beats Expectations

Financial news for ARIA dated on 2014-12-11: Morning Market Losers

Financial news for ARIA dated on 2014-12-11: Benzinga's Top #PreMarket Losers

Financial news for ARIA dated on 2014-12-11: UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak

Financial news for ARIA dated on 2014-12-11: Credit Suisse Downgrades ARIAD Pharmaceuticals, Inc. to Underperform, Lowers PT to \$6.00

Financial news for ARIA dated on 2014-12-09: ARIAD Reports Follow-up Data from Phase 1, PACE Trials of Ponatinib for T315I Mutation

Financial news for ARIA dated on 2014-12-08: ARIAD Reports Long-term Safety, Efficacy Data of Ponatinib from Phase 2 Pace Trial: 83% of CP-CML Patients Achieved Response

Financial news for ARIA dated on 2014-12-04: Option Alert: Ariad May \$10 Call; 1,000 Contract Trade at Ask @\$0.70; Currently \$7.44

Financial news for ARIA dated on 2014-12-04: Ariad Shares Up 1% Premarket on Rumor of Potential Bids from AstraZeneca, Shire

Financial news for ARIA dated on 2014-11-24: Morning Market Movers

Financial news for ARIA dated on 2014-11-24: ARIAD, STA Report Approval of Iclusig in Australia

Financial news for ARIA dated on 2014-11-21: Ariad Pharmaceuticals Chairman Berger Buys 25,000 Shares @\$6.15/Share -Form 4

Financial news for ARIA dated on 2014-11-06: Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals

Financial news for ARIA dated on 2014-11-05: ARIAD Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.27) vs \$(0.30) Est; Revenue of \$14.70M vs \$16.46M Est

Financial news for ARIA dated on 2014-11-05: Earnings Scheduled For November 5, 2014

Financial news for ARIA dated on 2014-10-24: ARIAD Reports Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe

Financial news for ARIA dated on 2014-10-10: UPDATE: ARIAD Announces PRAC Has Recommended No Change to Approved Indication in Europe

Financial news for ARIA dated on 2014-10-10: ARIAD Announces Recommendation For

Iclusig By The Pharmacovigilance Risk Assessment Committee Of The European Medicines Agency

Financial news for ARIA dated on 2014-10-09: Option Alert: Ariad Oct \$4.5 Call; 1,500 Contract Trade at Ask@\$1.00; Currently \$5.46

Financial news for ARIA dated on 2014-10-08: Option Alert: Ariad Oct \$4.5 Call; 2,000 Contract Trade at Ask@\$0.85; Currently \$5.22

Financial news for ARIA dated on 2014-10-06: ARIAD, Bellicum Report Revised License Deal for Co.'s Cell-Signaling Technology

Financial news for ARIA dated on 2014-10-02: Markets Mixed; Constellation Brands Posts Downbeat Profit

Financial news for ARIA dated on 2014-10-02: Morning Market Movers

Financial news for ARIA dated on 2014-10-02: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2014-10-02: ARIAD FDA Breakthrough Therapy Designation for AP26113 for ALK+ NSCLC Resistant to Crizotinib

Financial news for ARIA dated on 2014-09-29: ARIAD Offers Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer

Financial news for ARIA dated on 2014-09-11: Ariad Pharmaceuticals Chairman Berger Buys 25,000 Shares @\$6.27/Share -Form 4

Financial news for ARIA dated on 2014-09-02: Amended 13D Filing from Mark DiPaolo's Sarissa Capital on Ariad Pharma Shows Request for Poison Pill Waiver, Co. Said Request Was Breach of Standstill Pact

Financial news for ARIA dated on 2014-08-25: GNC, Southern Copper And Others Insiders Have Been Buying

Financial news for ARIA dated on 2014-08-08: 8-K from ARIAD Highlights Aug. 1st Disclosure by Adage and Several of Its Units (in 13G Filing) of 5.01% Stake in Co.

Financial news for ARIA dated on 2014-08-06: ARIAD Comments on Accelerating Patient Enrollment in ALTA Trial of AP26113

Financial news for ARIA dated on 2014-08-06: ARIAD Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.30) vs \$(0.29) Est; Revenue of \$12.10M vs \$13.87M Est

Financial news for ARIA dated on 2014-08-05: ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel

Financial news for ARIA dated on 2014-07-24: Morning Market Movers

Financial news for ARIA dated on 2014-07-24: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2014-07-23: Benzinga's M&A Chatter for Wednesday July 23, 2014

Financial news for ARIA dated on 2014-07-23: UPDATE: Fake Twitter Account Mentioned Shire Deal with Ariad to be Announced Tomorrow

Financial news for ARIA dated on 2014-07-23: Hearing Fake Deutsche Bank Twitter Account Responsible for Spike in Ariad Shares

Financial news for ARIA dated on 2014-07-23: Ariad Shares Now Up 15%, No Definitive News

Financial news for ARIA dated on 2014-07-14: ARIAD Announces Continuation of Iclusig Review Related to Article 20 Procedure in Europe

Financial news for ARIA dated on 2014-07-14: Ariad Announces Continuation Of Iclusig Review Under Article 20 Procedure In Europe

Financial news for ARIA dated on 2014-07-10: Ariad Pharmaceuticals Shares Move Higher; May be Attributed to Positive Stansberry Comments

Financial news for ARIA dated on 2014-06-19: Filing from Ariad Pharma Shows Strong Disagreement with June 12th ISS Report

Financial news for ARIA dated on 2014-06-12: Morning Market Losers

Financial news for ARIA dated on 2014-06-12: Ariad Announces \$12/Share Conversion For \$200M Note Offering

Financial news for ARIA dated on 2014-06-12: Benzinga's Top #PreMarket Losers

Financial news for ARIA dated on 2014-06-11: ARIAD Announces Proposed \$175M Offering of Convertible Senior Notes Due 2019

Financial news for ARIA dated on 2014-06-02: Market Wrap For June 2: Dow, S&P Continue Rising, Nasdaq Slightly Lower

Financial news for ARIA dated on 2014-06-02: Mid-Afternoon Market Update; ISM Revised Twice, CONN Maintains Gains On Earnings Report

Financial news for ARIA dated on 2014-06-02: Mid-Day Market Update: MasTec Tumbles On Weak Forecast; Protective Life Shares Spike Higher

Financial news for ARIA dated on 2014-06-02: Mid-Morning Market Update: Markets Fall; Conn's Profit Beats Street View

Financial news for ARIA dated on 2014-06-02: Morning Market Movers

Financial news for ARIA dated on 2014-06-02: UPDATE: Ariad Pharmaceuticals Shares Rise 11% Premarket Following Report of Positive Iclusig Data at ASCO

Financial news for ARIA dated on 2014-06-02: ARIAD Announces Positive Long Term Ponatinib Data

Financial news for ARIA dated on 2014-06-01: ARIAD Presents Initial Data from Phase 2 Trial of Iclusig in Patients with GIST at ASCO 2014

Financial news for ARIA dated on 2014-05-31: ARIAD Preliminary Safety and Efficacy Data of Ponatinib in Patients with Newly Diagnosed CML from Discontinued Phase 3 EPIC Trial

Financial news for ARIA dated on 2014-05-31: ARIAD Updated Phase 1/2 Data on AP26113 Presented at ASCO, Shows Anti-Tumor Activity in Patients with ALK+ NSCLC

Financial news for ARIA dated on 2014-05-07: Ariad Shares Move Lower. May be Attributed to Adam F/Street.com Article

Financial news for ARIA dated on 2014-05-07: ARIAD Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.27) vs \$(0.32) Est

Financial news for ARIA dated on 2014-05-07: Earnings Scheduled For May 7, 2014

Financial news for ARIA dated on 2014-05-05: Morning Market Movers

Financial news for ARIA dated on 2014-05-05: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2014-05-05: Jefferies Upgrades ARIAD Pharmaceuticals, Inc. to Outperform, Raises PT to \$14.00

Financial news for ARIA dated on 2014-04-25: Option Alert: Ariad Pharmaceuticals Shares Spike on 8,000 Contract Trade in the Jan \$20 Call; Currently \$7.06

Financial news for ARIA dated on 2014-04-23: Ariad Pharmaceuticals Spikes Higher

Financial news for ARIA dated on 2014-04-16: ARIAD to Report Q1 2014 Financial Results on Wednesday, May 7, 2014, Before the Market Opens

Financial news for ARIA dated on 2014-04-02: ARIAD Names Hugh Cole as Chief Business Officer

Financial news for ARIA dated on 2014-03-28: Market Wrap For March 28: Markets Still Positive Despite Giving Up Early Gains

Financial news for ARIA dated on 2014-03-28: Mid-Day Market Update: Restoration Hardware Surges On Earnings; Endocyte Shares Drop

Financial news for ARIA dated on 2014-03-28: Mid-Morning Market Update: Markets Open Higher; BlackBerry Reports Smaller-Than-Expected Loss

Financial news for ARIA dated on 2014-03-28: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2014-03-28: UPDATE: Ariad Pharmaceuticals Shares Rise 5% Premarket Following Thursday's UK Daily Mail Report of Rumored \$20 Bid from Jazz Pharmaceuticals

Financial news for ARIA dated on 2014-03-27: Daily Mail Reports Jazz Pharmaceuticals Willing to Pay \$20/Share for Ariad

Financial news for ARIA dated on 2014-03-25: HC Wainwright Upgrades ARIAD Pharmaceuticals, Inc. to Buy

Financial news for ARIA dated on 2014-03-25: Morning Market Movers

Financial news for ARIA dated on 2014-03-25: Ariad Shares Rise 3% Premarket Following HC Wainwright Resuming Coverage with Buy, \$14 PT

Financial news for ARIA dated on 2014-03-24: ARIAD Initiates Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer

Financial news for ARIA dated on 2014-03-19: roberto pedone tweet: The Next Big Biotech Mover: \$ARIA Ariad Pharma stks.co/s07GP My via @TheStreet

Financial news for ARIA dated on 2014-03-14: Top Trending Tickers On StockTwits For March 14

Financial news for ARIA dated on 2014-02-27: Ian Estepan Tweet: \$ARIA FT CEO says co in partnership discussions for Iclusig, expect an announcement soon - but what about that \$20 bid?

Financial news for ARIA dated on 2014-02-27: Ariad Spikes Higher on Volume

Financial news for ARIA dated on 2014-02-26: Maxim Group Upgrades ARIAD Pharmaceuticals, Inc. to Buy, Announces \$11.00 PT

Financial news for ARIA dated on 2014-02-26: Benzinga's Top Downgrades

Financial news for ARIA dated on 2014-02-26: Chardan Capital Downgrades ARIAD Pharmaceuticals, Inc. to Neutral, Maintains \$9.00 PT

Financial news for ARIA dated on 2014-02-25: Market Wrap For February 25: Markets End The Day Relatively Flat

Financial news for ARIA dated on 2014-02-25: Top Trending Tickers On StockTwits For February 25

Financial news for ARIA dated on 2014-02-25: ARIAD Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.40) vs \$(0.47) Est

Financial news for ARIA dated on 2014-02-25: Earnings Scheduled For February 25, 2014

Financial news for ARIA dated on 2014-02-24: ARIA Will Present at 34th Annual Health Care Conference Hosted by Cowen, Chair, CEO Berger Will Present Tues, Mar. 4th at 10:40AM EST

Financial news for ARIA dated on 2014-02-21: Market Wrap For February 21: Markets End The Week On A Negative Note

Financial news for ARIA dated on 2014-02-21: ARIAD Names Sarissa Capital Mgmt Representative to Board, Co. Will Also Appoint Added Independent Director

Financial news for ARIA dated on 2014-02-21: ARIAD Names Alexander J. Denner, Ph.D. of Sarissa Capital Management to Board

Financial news for ARIA dated on 2014-02-20: Ariad Spikes Higher; May be Attributed to Stansberry Report

Financial news for ARIA dated on 2014-02-19: ARIAD Says Will Present at RBC Capital Markets Healthcare Conference on Wednesday, Feb. 26th

Financial news for ARIA dated on 2014-02-07: Credit Suisse Reports Ariad's Iclusig is 'Essential Drug'

Financial news for ARIA dated on 2014-02-07: Credit Suisse Maintains Neutral on ARIAD Pharmaceuticals, Inc., Raises PT to \$8.00

Financial news for ARIA dated on 2014-02-06: UPDATE: Sarissa Capital Management Indicated Interest in Obtaining Seats on Ariad's Board in a 13D Filing on October 29, 2013

Financial news for ARIA dated on 2014-02-06: Shares of ARIAD Selling Off from Post-Market Highs as Word of Sarissa Interest Originally Reported Late Last Year

Financial news for ARIA dated on 2014-02-06: Ariad Spikes Higher

Financial news for ARIA dated on 2014-02-06: Reuters Reporting Sarissa Capital Looking for Board Seats at ARIAD

Financial news for ARIA dated on 2014-01-28: Tug Of War In Ariad Pharmaceuticals

Financial news for ARIA dated on 2014-01-28: ARIAD Announces Commercial Deal for Iclusig in Australia

Financial news for ARIA dated on 2014-01-27: Benzinga's M&A Chatter for Monday January 27, 2014

Financial news for ARIA dated on 2014-01-27: Adam F Tweet: '\$ARIA Short Seller Explains Why Takeover Rumor is Bunk'

Financial news for ARIA dated on 2014-01-27: Top Trending Tickers On StockTwits For January 27

Financial news for ARIA dated on 2014-01-24: Market Wrap For January 24: Fear Is Back In The Markets

Financial news for ARIA dated on 2014-01-24: Ariad Shares Continue to Surge Amidst Buyout Rumors

Financial news for ARIA dated on 2014-01-24: Ariad Pharmaceuticals Continues To Rally

Financial news for ARIA dated on 2014-01-24: Mid-Afternoon Market Update: Markets Get Hammered on China Fears as Microsoft Provides one of the Few Havens of Strength

Financial news for ARIA dated on 2014-01-24: Option Alert: Ariad Jan 2015 \$20 Call; 8,000 Contract Trade Between Bid and Ask @\$0.75; Currently \$9.50

Financial news for ARIA dated on 2014-01-24: BMO Capital Upgrades ARIAD Pharmaceuticals, Inc. to Outperform, Raises PT to \$14.00

Financial news for ARIA dated on 2014-01-24: Ariad Spikes Higher

Financial news for ARIA dated on 2014-01-23: Top Trending Tickers On StockTwits For January 23

Financial news for ARIA dated on 2014-01-23: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2014-01-22: Benzinga's M&A Chatter for Wednesday January 22, 2014

Financial news for ARIA dated on 2014-01-22: UK Daily Mail Reports Aria Approached by Big Pharma, Including Lilly

Financial news for ARIA dated on 2014-01-22: Ariad Spikes Higher

Financial news for ARIA dated on 2014-01-17: Market Wrap For January 17: Stocks Finish Week With Mixed Results

Financial news for ARIA dated on 2014-01-17: Top Trending Tickers On StockTwits For January 17

Financial news for ARIA dated on 2014-01-17: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2014-01-17: ARIAD Announces Commercial Availability of Iclusig for Patients with Refractory Philadelphia-Positive Leukemias in US

Financial news for ARIA dated on 2014-01-15: Benzinga's Top #PreMarket Losers

Financial news for ARIA dated on 2014-01-14: UPDATE: Ariad Says Eligible to Receive Additional Regulatory, Clinical and Commercial Milestones of Up to \$34.75M if Two Products Developed

Financial news for ARIA dated on 2014-01-14: ARIAD, Medinol Start Two Studies of Nirsupreme Stent

Financial news for ARIA dated on 2014-01-13: UPDATE: JMP Securities Reiterates Coverage on ARIAD Pharmaceuticals, Sees Market Share Regain

Financial news for ARIA dated on 2014-01-06: Market Wrap For January 6: Busy Day For Analysts Upgrades and Downgrades

Financial news for ARIA dated on 2014-01-06: UPDATE: Ariad Pharmaceuticals Downgraded by Citigroup

Financial news for ARIA dated on 2014-01-06: Benzinga's Top #PreMarket Losers

Financial news for ARIA dated on 2014-01-06: Benzinga's Top Downgrades

Financial news for ARIA dated on 2014-01-06: Citigroup Downgrades ARIAD Pharmaceuticals, Inc. to Sell, Raises PT to \$5.50

Financial news for ARIA dated on 2014-01-02: Market Wrap For January 2: Markets Begin 2014 on Negative Note

Financial news for ARIA dated on 2014-01-02: Mid-Afternoon Market Update: Markets Look to Close Red as Solar Stocks Show Strength

Financial news for ARIA dated on 2014-01-02: Mid-Day Market Update: ANN Surges On Analyst Upgrade; DryShips Shares Decline

Financial news for ARIA dated on 2014-01-02: Mid-Morning Market Update: Markets Tumble; Fiat To Acquire Rest Of Chrysler

Financial news for ARIA dated on 2014-01-02: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2014-01-02: ARIAD to Present at JP Morgan Healthcare Conference on Tuesday, January 14 at 6:00 PM ET

Financial news for ARIA dated on 2013-12-31: Ariad Spikes to High

Financial news for ARIA dated on 2013-12-31: Ariad Spikes Higher

Financial news for ARIA dated on 2013-12-30: Ariad Spikes Lower

Financial news for ARIA dated on 2013-12-27: Mid-Day Market Update: US Markets Turn Lower; Twitter Shares Fall On Analyst Downgrade

Financial news for ARIA dated on 2013-12-27: Mid-Morning Market Update: Markets Mostly Higher; Textron To Acquire Beechcraft For \$1.4B

Financial news for ARIA dated on 2013-12-23: UPDATE: Credit Suisse Raises PT on Ariad Pharmaceuticals, View Remains Cautious

Financial news for ARIA dated on 2013-12-23: JMP Securities Upgrades ARIAD Pharmaceuticals, Inc. to Market Outperform, Announces \$10.00 PT

Financial news for ARIA dated on 2013-12-23: UPDATE: Bank of America Reiterates on Ariad Pharmaceuticals Following News of Iclusig Re-Launch

Financial news for ARIA dated on 2013-12-23: Chardan Capital Upgrades ARIAD Pharmaceuticals, Inc. to Buy

Financial news for ARIA dated on 2013-12-23: UPDATE: Credit Suisse Reiterates on Ariad Pharmaceuticals as Iclusig Re-Launch is Expected to be Bumpy

Financial news for ARIA dated on 2013-12-23: Benzinga's Top Upgrades

Financial news for ARIA dated on 2013-12-23: William Blair Upgrades ARIAD Pharmaceuticals, Inc. to Outperform, Raises PT to \$12.00

Financial news for ARIA dated on 2013-12-23: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2013-12-23: Credit Suisse Maintains Neutral on ARIAD Pharmaceuticals, Inc., Raises PT to \$5.00

Financial news for ARIA dated on 2013-12-20: ARIAD Resumes Marketing and Distribution of Iclusig, Investors Getting Some Relief

Financial news for ARIA dated on 2013-12-20: Ariad Conference Call Ends

Financial news for ARIA dated on 2013-12-20: Ariad Expects Iclusig Trials to Come off Partial Hold Soon

Financial news for ARIA dated on 2013-12-20: Ariad Sees Added Trials to Come off Partial Clinical Hold

Financial news for ARIA dated on 2013-12-20: Ariad Not Aware of FDA Plans for Advisory Committee Panel

Financial news for ARIA dated on 2013-12-20: Ariad Says Iclusig Label Now has Warning for Heart Failure

Financial news for ARIA dated on 2013-12-20: Ariad Says Iclusig Same Today as it was 3 Months and 6 Months Ago

Financial news for ARIA dated on 2013-12-20: Ariad Iclusig Conference Call Begins

Financial news for ARIA dated on 2013-12-20: NYSE Will Bust Trades in ARIA Between 09:58:07-10:03:07AM EST and 10:09:55-10:14:55AM

Financial news for ARIA dated on 2013-12-20: NYSE Announces Erroneous Trades in ARIA

Financial news for ARIA dated on 2013-12-20: ARIAD Halted on Yet Another Circuit Breaker, Stock Now Up 26%

Financial news for ARIA dated on 2013-12-20: UPDATE: Ariad Says Commercialization of Iclusig to be Cash-Flow Positive from Onset

Financial news for ARIA dated on 2013-12-20: UPDATE: FDA Approves Revised US Iclusig Prescribing Info, Risk Evaluation And Mitigation Strategy

Financial news for ARIA dated on 2013-12-20: UPDATE: ARIAD Announces US Resumption Of Marketing And Comm'l Distribution Of Iclusig In Refractory Philadelphia-Positive Leukemias

Financial news for ARIA dated on 2013-12-20: ARIAD Shares Halted on Fourth Breaker, Stock is Up 14%

Financial news for ARIA dated on 2013-12-20: ARIAD Halted on Third Circuit Breaker, Now Down to Up 25.5%

Financial news for ARIA dated on 2013-12-20: ARIAD Shares Resume, Now Up 27%

Financial news for ARIA dated on 2013-12-20: ARIAD Halted Once Again, Stock Up 31%

Financial news for ARIA dated on 2013-12-20: ARIAD Shares Halted on Circuit Breaker, Stopped Up Nearly 16%, Should Resume Trade in About 2 Mins

Financial news for ARIA dated on 2013-12-20: Ariad Shares Halted on Circuit Breaker; Expected to Resume Trading at 9:57:42

Financial news for ARIA dated on 2013-12-20: ARIAD Gets US Approval to Bring Iclusig Back to Market, Will Start Selling Again by Mid-Jan

Financial news for ARIA dated on 2013-12-18: Stocks to Watch for December 18, 2013

Financial news for ARIA dated on 2013-12-17: UPDATE: EMA Says Will Discuss Voluntary Withdrawal of Janssen's Doribax, Risk-Benefit Balance of ARIAD's Iclusig

Financial news for ARIA dated on 2013-12-17: EMA Puts Aria's Iclusig on Agenda for this Week

Financial news for ARIA dated on 2013-12-10: Mid-Day Market Update: Pep Boys Tumbles On Downbeat Results; Rambus Shares Jump

Financial news for ARIA dated on 2013-12-10: Stocks to Watch for December 10, 2013

Financial news for ARIA dated on 2013-12-10: UPDATE: Stifel Upgrades Ariad Pharmaceuticals on Physician Enthusiasm at ASH

Financial news for ARIA dated on 2013-12-10: Mid-Morning Market Update: Markets Edge Lower; Toll Brothers Profit Tops Estimates

Financial news for ARIA dated on 2013-12-10: Stifel Nicolaus Upgrades ARIAD Pharmaceuticals, Inc. to Buy

Financial news for ARIA dated on 2013-12-03: UPDATE: Ariad Says Doesn't have Any News or Any Timelines for Any News Regarding FDA Lifting Marketing Ban on Iclusig

Financial news for ARIA dated on 2013-12-03: Ariad Confirms Discussions with FDA Regarding Lifting Ban on Iclusig; Says Any Material News Would be Announced in a Press Release

Financial news for ARIA dated on 2013-12-03: Hearing Unconfirmed Market Chatter FDA to Lift Ban on Iclusig

Financial news for ARIA dated on 2013-12-02: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2013-11-29: Benzinga's Top #PreMarket Losers

Financial news for ARIA dated on 2013-11-25: Market Wrap For November 25: Nasdaq Breaks 4,000 Level For First Time Since 2000

Financial news for ARIA dated on 2013-11-25: Stocks to Watch for November 25, 2013

Financial news for ARIA dated on 2013-11-25: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2013-11-22: Market Wrap For November 22: Markets Finish The Week On a Positive Note

Financial news for ARIA dated on 2013-11-22: Ariad Pharmaceuticals Able to Continue Its EU Iclusig Sales

Financial news for ARIA dated on 2013-11-22: Mid-Afternoon Market Update: Markets on the Rise as Intel Falls

Financial news for ARIA dated on 2013-11-22: Mid-Day Market Update: US Stocks Gain; Fresh Market Shares Decline On Weak Results

Financial news for ARIA dated on 2013-11-22: Mid-Morning Market Update: Markets Open Mixed; Foot Locker Profit Beats Estimates

Financial news for ARIA dated on 2013-11-22: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2013-11-22: EMA Recommends Changes in Use of Ariad's Iclusig

Financial news for ARIA dated on 2013-11-18: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2013-11-12: ARIAD Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.36) vs \$(0.43) Est; Revenue of \$16.70M vs \$16.66M Est

Financial news for ARIA dated on 2013-11-11: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2013-11-08: EMA's PRAC Updates On The Risks Of Serious Vascular Occlusive Events Associated With Cancer Medicine Iclusig

Financial news for ARIA dated on 2013-11-07: ARIAD to Cut 40% of US Staff Positions

Financial news for ARIA dated on 2013-11-04: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2013-11-01: ARIAD Adopts Holder Rights Plan, Cites Preserving NOL Carryforwards, Other Tax Benefits

Financial news for ARIA dated on 2013-11-01: Leerink Swann Downgrades ARIAD Pharmaceuticals, Inc. to Market Perform

Financial news for ARIA dated on 2013-10-31: ARIAD Changes Date of Q3 2013 Financial Results Conference Call and Webcast to November 12, 2013

Financial news for ARIA dated on 2013-10-31: Guggenheim Securities Downgrades ARIAD Pharmaceuticals, Inc. to Neutral, Lowers PT to \$3.00

Financial news for ARIA dated on 2013-10-31: Stocks Hitting 52-Week Lows

Financial news for ARIA dated on 2013-10-31: ARIAD Pharma's Webcast on Iclusig Concludes

Financial news for ARIA dated on 2013-10-31: From ARIAD Call: Working with FDA on Addressing Current Patient Needs

Financial news for ARIA dated on 2013-10-31: ARIAD Currently Holding Call to Discuss Suspended Iclusig Marketing: Says Doesn't Believe Suspension Was the Only Strategy, However FDA 'Preferred Strongly' for Suspension

Financial news for ARIA dated on 2013-10-31: ARIAD Currently Holding Call to Discuss Suspended Iclusig Marketing: Says Doesn't Believe Suspension Was the Only Strategy, However FDA 'Preferred Strongly' for Suspension

Financial news for ARIA dated on 2013-10-31: Benzinga's Top #PreMarket Losers

Financial news for ARIA dated on 2013-10-31: UPDATE: Ariad Falls 30% Pre-Market on Iclusig Marketing Suspension

Financial news for ARIA dated on 2013-10-31: ARIAD Reports Temporary Suspension of Iclusig Marketing in US

Financial news for ARIA dated on 2013-10-31: #PreMarket Primer: Thursday, October 31: BOJ Bullish On Inflation

Financial news for ARIA dated on 2013-10-30: Market Wrap for October 30: Fed Worries Push Stocks Lower, Facebook Earnings Raise Concerns

Financial news for ARIA dated on 2013-10-30: Mid-Day Market Update: US Stocks Turn

Lower; Electronic Arts Shares Rise On Upbeat Earnings

Financial news for ARIA dated on 2013-10-30: Mid-Morning Market Update: Markets Open Higher; GM Profit Tops Estimates

Financial news for ARIA dated on 2013-10-30: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2013-10-29: 13D Filing from Sarissa Shows 6.22% Stake in ARIAD Pharma

Financial news for ARIA dated on 2013-10-28: Benzinga's Top #PreMarket Gainers

Financial news for ARIA dated on 2013-10-22: Benzinga's Top Pre-Market Gainers

Financial news for ARIA dated on 2013-10-21: William Blair Downgrades ARIAD Pharmaceuticals, Inc. to Market Perform

Financial news for ARIA dated on 2013-10-21: HC Wainwright Downgrades ARIAD Pharmaceuticals, Inc. to Neutral, Lowers to \$2.50

Financial news for ARIA dated on 2013-10-21: Oppenheimer Downgrades ARIAD Pharmaceuticals, Inc. to Perform, Removes \$7.00 PT

Financial news for ARIA dated on 2013-10-18: Market Wrap For Friday, October 18: Markets Continue to Make New Highs On Upbeat Earnings

Financial news for ARIA dated on 2013-10-18: Mid-Afternoon Market Update: S&P 500 and Google Both Look to Close at Record Highs

Financial news for ARIA dated on 2013-10-18: Mid-Day Market Update: Google Jumps On Upbeat Results; Acacia Research Shares Drop

Financial news for ARIA dated on 2013-10-18: Mid-Morning Market Update: Markets Mostly Higher; GE Profit Beats Estimates

Financial news for ARIA dated on 2013-10-18: Stocks Hitting 52-Week Lows

Financial news for ARIA dated on 2013-10-18: ARIAD Shares Halted on Circuit Breaker, Down 36% to \$2.86

Financial news for ARIA dated on 2013-10-18: Bloomberg Reporting ARIAD Pharma Has Said FDA ODAC Panel for Iclusig Likely Next Year

Financial news for ARIA dated on 2013-10-18: ARIAD Call Just Beginning: Chief Science Officer Says Co. to Focus on Iclusig in Refractory CML Patients, Says Does Not Expect Iclusig to be Pulled from Market

Financial news for ARIA dated on 2013-10-18: Benzinga's Top Pre-Market Losers

Financial news for ARIA dated on 2013-10-18: ARIAD Pharma Shares Resume Trading Down 35% to ~\$2.83

Financial news for ARIA dated on 2013-10-18: PREVIEW: ARIAD Pharmaceuticals to Resume Trading at 7:30 AM ET

Financial news for ARIA dated on 2013-10-18: UPDATE: ARIAD Reports Discontinuation of Phase 2 EPIC Trial of Iclusig

Financial news for ARIA dated on 2013-10-18: ARIAD Reports Discontinuation of Phase 2 EPIC Trial of Iclusig

Financial news for ARIA dated on 2013-10-18: ARIAD Pharmaceuticals Halted; Pending News

Financial news for ARIA dated on 2013-10-14: Mid-Morning Market Update: Markets Open Lower; Facebook Acquires Onavo

Financial news for ARIA dated on 2013-10-11: Ariad Shares Fall 18% on FDA Bulletin, Adam F Tweet

Financial news for ARIA dated on 2013-10-11: Ariad Shares Fall 18% on FDA Bulletin, Adam F Tweet

Financial news for ARIA dated on 2013-10-11: Report Newly Identified Serious Adverse Reactions Reported Involving in Eyes of Patients Treated With Iclusig

Financial news for ARIA dated on 2013-10-10: Mid-Afternoon Market Update: Vonage Rises on Acquisition Amid Huge Market Rally

Financial news for ARIA dated on 2013-10-10: Mid-Day Market Update: Dow Goes Above 15000; iGATE Shares Gain On Upbeat Results

Financial news for ARIA dated on 2013-10-10: UPDATE: Barclays Downgrades Ariad Pharmaceuticals Following News of Iclusig Clinical Hold

Financial news for ARIA dated on 2013-10-10: UPDATE: JMP Securities Downgrades Ariad Pharmaceuticals Following Announcement of Partial Hold on Iclusig Trials

Financial news for ARIA dated on 2013-10-10: Mid-Morning Market Update: Markets Rally; Citrix Lowers Q3 Outlook

Financial news for ARIA dated on 2013-10-10: UPDATE: Bank of America Downgrades Ariad Pharmaceuticals on Uncertain Iclusig Outlook

Financial news for ARIA dated on 2013-10-10: Chardan Capital Downgrades ARIAD Pharmaceuticals, Inc. to Neutral, Removes \$26.00 PT

Financial news for ARIA dated on 2013-10-10: Benzinga's Top Pre-Market Losers

Financial news for ARIA dated on 2013-10-10: Benzinga's Top Downgrades

Financial news for ARIA dated on 2013-10-10: Citigroup Downgrades ARIAD Pharmaceuticals, Inc. to Neutral

Financial news for ARIA dated on 2013-10-10: JMP Securities Downgrades ARIAD Pharmaceuticals, Inc. to Market Perform

Financial news for ARIA dated on 2013-10-10: Maxim Group Downgrades ARIAD Pharmaceuticals, Inc. to Hold

Financial news for ARIA dated on 2013-10-10: Adam Feuerstein Tweet: 'I had dinner last night w/ 1 of 2 buysiders who called \$ARIA short perfectly. His next best short idea is \$VNDA. FDA panel disaster Nov. 14'

Financial news for ARIA dated on 2013-10-10: Barclays Downgrades ARIAD Pharmaceuticals, Inc. to Underweight, Lowers PT to \$4.00

Financial news for ARIA dated on 2013-10-09: Market Wrap for Wednesday, October 9: Yellen Nominated, Markets Closed Mixed

Financial news for ARIA dated on 2013-10-09: Mid-Afternoon Market Update: Markets Give Up Some Ground as Darden Rises on Activist Stake

Financial news for ARIA dated on 2013-10-09: Bank of America Downgrades ARIAD Pharmaceuticals, Inc. to Neutral

Financial news for ARIA dated on 2013-10-09: Brean Capital Downgrades ARIAD Pharmaceuticals, Inc. to Hold

Financial news for ARIA dated on 2013-10-09: Mid-Day Market Update: US Stocks Slide; Alcoa Shares Surge On Upbeat Results

Financial news for ARIA dated on 2013-10-09: Mid-Morning Market Update: US Markets Mixed; Family Dollar Posts Rise In Q4 Profit

Financial news for ARIA dated on 2013-10-09: Ariad Halted Third Time on Circuit Breaker

Financial news for ARIA dated on 2013-10-09: Ariad Resumes Trading, Down 76%

Financial news for ARIA dated on 2013-10-09: Ariad Pharmaceuticals Halted on Second Circuit Breaker

Financial news for ARIA dated on 2013-10-09: Option Alert: Ariad Pharmaceuticals January 6 Call; 2,000 Contracts Traded @\$0.50, Currently \$4.06

Financial news for ARIA dated on 2013-10-09: Stocks Hitting 52-Week Lows

Financial news for ARIA dated on 2013-10-09: Morning Market Losers

Financial news for ARIA dated on 2013-10-09: Benzinga's Top Pre-Market Losers

Financial news for ARIA dated on 2013-10-09: ARIAD Pharma Shares Resume Trade Down 56%

Financial news for ARIA dated on 2013-10-09: ARIAD Pharma Shares to Resume Trade at 7:30AM EDT

Financial news for ARIA dated on 2013-10-09: UPDATE: ARIAD Says Pausing Enrollment in Studies of Iclusig

Financial news for ARIA dated on 2013-10-09: ARIAD Says Pausing Enrollment in Studies of Iclusig

Financial news for ARIA dated on 2013-09-30: UPDATE: BMO Capital Markets Downgrades Ariad Pharmaceuticals on AP26113 Disappointment, Tempered ICLUSIG Expectations

Financial news for ARIA dated on 2013-09-30: Shares of Clovis Oncology Down 4+% Following Mixed Ariad Data on AP26113, Data on AZD9291 from AstraZeneca

Financial news for ARIA dated on 2013-09-30: BMO Capital Downgrades ARIAD Pharmaceuticals, Inc. to Market Perform, Lowers PT to \$21.00

Financial news for ARIA dated on 2013-09-30: UPDATE: Oppenheimer Upgrades Ariad Pharmaceuticals on Revised Outlook Following Recent Updates

Financial news for ARIA dated on 2013-09-30: Benzinga's Top Pre-Market Gainers

Financial news for ARIA dated on 2013-09-30: Benzinga's Top Upgrades

Financial news for ARIA dated on 2013-09-30: Oppenheimer Upgrades ARIAD Pharmaceuticals, Inc. to Outperform, Raises PT to \$24.00

Financial news for ARIA dated on 2013-09-28: ARIAD Presents Positive Phase 1/2 Trial Data on AP26113 in Patients with Non-Small Cell Lung Cancer at ECC 2013

Financial news for ARIA dated on 2013-09-17: H.C. Wainwright & Co Initiates Coverage on ARIAD Pharmaceuticals, Inc. at Buy, Announces \$26.00 PT

Financial news for ARIA dated on 2013-09-06: Ariad Spokesperson Says No News Released Today to Account for Strength

Financial news for ARIA dated on 2013-09-06: Ariad Pharmaceuticals Spikes to Highs

Financial news for ARIA dated on 2013-09-04: ARIAD Pharma Shares Push Over \$20, Now Up Nearly 5% Following New Buy Rating, \$28 Target at Chardan

Financial news for ARIA dated on 2013-09-04: ARIAD Pharma Reports Achievement of 50% Patient Enrollment in Phase 3 EPIC Trial of Iclusig

Financial news for ARIA dated on 2013-08-26: These ETFs House The Next Biotech Takeover Targets

Financial news for ARIA dated on 2013-08-07: ARIAD Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.37) vs \$(0.40) Est; Revenue of \$14.0M vs \$11.10M Est

Financial news for ARIA dated on 2013-07-17: ARIAD Names Sarah J. Schlesinger, M.D. of Rockefeller University to Its Board of Directors

Financial news for ARIA dated on 2013-07-16: Credit Suisse Initiates Coverage on ARIAD Pharmaceuticals, Inc. at Neutral, Announces \$22.00 PT

Financial news for ARIA dated on 2013-07-16: Credit Suisse Initiates Coverage on ARIAD Pharmaceuticals, Inc. at Neutral

Financial news for ARIA dated on 2013-07-02: BMO Says Biotech Sector Could See Upside from M&A, Offers Multiple Attractive Targets

Financial news for ARIA dated on 2013-07-02: Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)

Financial news for ARIA dated on 2013-07-02: ARIAD Pharma Reports Marketing Authorization for Iclusig in EU

Financial news for ARIA dated on 2013-07-01: Afternoon Market Gainers

Financial news for ARIA dated on 2013-07-01: Bernstein Believes Onyx Pharma Bid Would Need to be in \$140-150/Share Range to Sufficiently Entice Management

Financial news for ARIA dated on 2013-06-11: Ariad Announces Commencement of Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors

Financial news for ARIA dated on 2013-06-03: Mid-Day Market Update: Markets Turn Mixed, Colonial Properties Gains On Acquisition News

Financial news for ARIA dated on 2013-06-02: ARIAD Presents Long-Term Durability-of-Response Data from Phase 1 Trial of Iclusig

Financial news for ARIA dated on 2013-06-02: ARIAD Announces Updated Clinical Results on AP26113 in Patients with Non-Small Cell Lung Cancer

Financial news for ARIA dated on 2013-06-01: ARIAD Announces Analysis of Cardiovascular Risk Profile of Patients in Pivotal PACE Trial of Iclusig

Financial news for ARIA dated on 2013-05-20: UPDATE: Ariad CEO Says Expecting Mid-2014 Japanese Regulatory Submission for Iclusig, Sees Iclusig Epic Trial Full Patient Enrollment by End of 2013, Sees Q3 Interim Analysis for Trial

Financial news for ARIA dated on 2013-05-20: Ariad Pharma CEO Speaking at UBS Conference: Expecting 'Strong Launch of Iclusig in US' in 2013, Sees Q3 AP26113 Pivotal Trial in Parallel with Phase 2

Financial news for ARIA dated on 2013-05-16: Benzinga's Top Pre-Market Losers

Financial news for ARIA dated on 2013-05-15: Dan' Loeb's Third Point Reporting it has Increased its Stake in Ariad Pharma from 2.5M Shares to 2.75M Shares

Financial news for ARIA dated on 2013-05-07: ARIAD Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.36) vs \$(0.38) Est; Revenue of \$6.40M vs \$5.01M Est

Financial news for ARIA dated on 2013-04-09: ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors

Financial news for ARIA dated on 2013-04-08: ARIAD Pharma Says Ponatinib Shown to Potently Inhibit RET, FGFR

Financial news for ARIA dated on 2013-04-04: From ARIAD's Business Call Update: Sees Q3 Next Year Primary Endpoint, Safety Data Completed, Disputes Alleged Toxicity of Iclusig

Financial news for ARIA dated on 2013-04-04: ARIAD Issues Update on R&D, Commercial Initiatives

Financial news for ARIA dated on 2013-04-03: Ariad Pharma Shares Fall as Analyst Concerned with Results from Recent Iclusig Survey

Financial news for ARIA dated on 2013-03-28: UPDATE: Goldman Sachs Initiates Ariad Pharmaceuticals with Neutral Rating on Fair Valuation

Financial news for ARIA dated on 2013-03-28: Goldman Sachs Initiates Coverage on ARIAD Pharmaceuticals, Inc. at Neutral, Announces \$20.00 PT

Financial news for ARIA dated on 2013-03-27: Report of Weak Leukemia Drug Prescriptions Affecting Ariad

Financial news for ARIA dated on 2013-03-22: UPDATE: ARIAD Confirms Positive CHMP Opinion for Iclusig Approval in EU

Financial news for ARIA dated on 2013-03-22: EMA Gives Positive Opinion's on Baxter's Hyqvia, ARIAD Pharma's Iclusig, Gilead's Stribild

Financial news for ARIA dated on 2013-03-20: UPDATE: Bank of America Raises PT on Ariad Pharmaceuticals Following Oncology Survey

Financial news for ARIA dated on 2013-03-20: ARIAD to Present Preclinical Data at AACR Annual Meeting

Financial news for ARIA dated on 2013-03-13: Maxim Group Maintains Buy on ARIAD Pharmaceuticals, Inc., Raises PT to \$26.00

Financial news for ARIA dated on 2013-02-27: Ariad CEO Berger: 'Pricing for Iclusig in Europe will Not be the Same as in US'

Financial news for ARIA dated on 2013-02-27: Ariad CEO Berger: ''We Think Iclsusig Could do Over \$1B'

Financial news for ARIA dated on 2013-02-27: Ariad CEO Berger: 'Iclusig was Approved in Just 5 Years'

Financial news for ARIA dated on 2013-02-27: Jim Cramer Interviews CEO Harvey Berger of Ariad Pharmaceutical on Mad Money

Financial news for ARIA dated on 2013-02-25: ARIAD Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.36) vs \$(0.35) Est

Financial news for ARIA dated on 2013-02-25: Earnings Scheduled For February 25, 2013

Financial news for ARIA dated on 2013-02-14: UPDATE: Stifel Nicolaus Cuts PT to \$26 on Ariad Pharmaceuticals on Tempered Iclusig Outlook

Financial news for ARIA dated on 2013-02-14: Stifel Nicolaus Maintains Buy on ARIAD Pharmaceuticals, Inc., Lowers PT to \$26.00

Financial news for ARIA dated on 2013-02-08: From Earlier: JMP Securities Initiates Coverage on ARIAD Pharmaceuticals, Inc. at Market Outperform, Announces \$32.00 PT

Financial news for ARIA dated on 2013-02-05: Ariad Pharmaceuticals Moves Lower on Seeking Alpha Article, Says Shares Overvalued

Financial news for ARIA dated on 2013-01-29: ARIAD Announces Completion of Public Offering

Financial news for ARIA dated on 2013-01-29: ARIAD Closes Public Offering, Sees Proceeds \$310M After Items

Financial news for ARIA dated on 2013-01-24: Ariad Prices 15.31M Shares at \$19.60/Share

Financial news for ARIA dated on 2013-01-07: ARIAD, UK National Cancer Research Institute to Collaborate on SPIRIT 3 Phase 3 Trial

Financial news for ARIA dated on 2012-12-17: UPDATE: Maxim Group Cuts PT to \$24 on ARIAD Pharmaceuticals; Label Warning Reduces Forecast

Financial news for ARIA dated on 2012-12-17: UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Ariad Pharmaceuticals

Financial news for ARIA dated on 2012-12-17: Maxim Group Reiterates Buy on ARIAD Pharmaceuticals, Inc., Lowers PT to \$24.00

Financial news for ARIA dated on 2012-12-17: Benzinga's Top Pre-Market Gainers

Financial news for ARIA dated on 2012-12-14: Citigroup Reiterates Buy Rating, \$31 PT on Ariad Pharmaceuticals

Financial news for ARIA dated on 2012-12-14: ARIAD Confirms Accelerated FDA Approval of Iclusig

Financial news for ARIA dated on 2012-12-14: Ariad Spikes Lower

Financial news for ARIA dated on 2012-12-14: FDA Approves Aria Pharma's Iclusig to Treat Two Rare Types of Leukemia

Financial news for ARIA dated on 2012-12-14: Ariad Spikes Higher

Financial news for ARIA dated on 2012-12-11: ARIAD Offers 12-Mo. Data from Pivotal PACE Trial of Ponatinib

Financial news for ARIA dated on 2012-12-09: ARIAD Reports Positive 12-Month Data from Pivotal PACE Trial of Ponatinib in Heavily Pretreated Chronic-Phase CML Patients

Financial news for ARIA dated on 2012-12-07: UPDATE: Dawson James Initiates Coverage on Ariad Pharmaceuticals with Market Outperform Rating, \$32 PT

Financial news for ARIA dated on 2012-12-07: Dawson James Initiates Coverage on ARIAD Pharmaceuticals, Inc. at Market Outperform, Announces \$32.00 PT

Financial news for ARIA dated on 2012-11-28: ARIAD Pharma Publishes Phase 1 Trial Results of Ponatinib in NEJOM

Financial news for ARIA dated on 2012-11-13: ARIAD , Foundation Medicine Announce Collaboration on AP26113 Study

Financial news for ARIA dated on 2012-11-08: Maxim Group Maintains Ariad Pharmaceuticals at Buy, Lowers PT from \$28 to \$26

Financial news for ARIA dated on 2012-11-07: Ariad Pharmaceuticals Reports Q3 EPS \$-0.32 vs \$-0.32 Est; Revenues \$85K vs \$1.11M Est

Financial news for ARIA dated on 2012-11-07: Ariad Pharmaceuticals Reports Q3 EPS \$-0.32 vs \$-0.32 Est; Revenues \$85K vs \$1.11M Est

Financial news for ARIA dated on 2012-10-26: UPDATE: Citigroup Initiates Ariad Pharmaceuticals at Buy

Financial news for ARIA dated on 2012-10-25: Citigroup Initiates Coverage on Ariad Pharmaceuticals at Buy

Financial news for ARIA dated on 2012-10-24: ARIAD Announces FDA Acceptance of NDA Filing for Ponatinib

Financial news for ARIA dated on 2012-10-22: Barclays Maintains Ariad Pharmaceuticals at Overweight, Raises PT from \$25 to \$30

Financial news for ARIA dated on 2012-10-22: UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Ariad Pharmaceuticals

Financial news for ARIA dated on 2012-10-22: Jefferies & Company Maintains Ariad Pharmaceuticals at Buy, Lowers PT from \$28 to \$27

Financial news for ARIA dated on 2012-10-22: Jefferies & Company Maintains Ariad Pharmaceuticals at Buy, Lowers PT from \$28 to \$27

Financial news for ARIA dated on 2012-10-19: Jefferies & Company Maintains Ariad Pharmaceuticals at Buy, Lowers PT from \$28 to \$27

Financial news for ARIA dated on 2012-10-03: Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

Financial news for ARIA dated on 2012-10-02: JP Morgan Maintains Ariad Pharmaceuticals at Overweight, Raises PT from \$23 to \$28

Financial news for ARIA dated on 2012-10-02: UBS Maintains Ariad Pharmaceuticals at Buy, Raises PT from \$23 to \$29

Financial news for ARIA dated on 2012-10-02: Jefferies & Company Maintains Ariad Pharmaceuticals at Buy, Raises PT from \$21 to \$28

Financial news for ARIA dated on 2012-10-01: Maxim Group Reiterates Buy Rating, \$28 PT on Ariad Pharmaceuticals

Financial news for ARIA dated on 2012-10-01: UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PO on Ariad Pharmaceuticals

Financial news for ARIA dated on 2012-10-01: Brean Murray Raises PT on Ariad Pharmaceuticals from \$19 to \$35

Financial news for ARIA dated on 2012-10-01: Stifel Nicolaus Maintains Ariad Pharmaceuticals at Buy, Raises PT from \$24 to \$25

Financial news for ARIA dated on 2012-10-01: Bank of America Maintains Ariad Pharmaceuticals at Buy, Raises PO from \$26 to \$30

Financial news for ARIA dated on 2012-09-27: ARIAD Completes Rolling Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration

Financial news for ARIA dated on 2012-09-18: Maxim Group Maintains Ariad Pharmaceuticals at Buy, Raises PT from \$24 to \$28

Financial news for ARIA dated on 2012-09-18: MolecularMD Withdraws Premarketing Approval Application from FDA for its BCR-ABL T315I Mutation Test

Financial news for ARIA dated on 2012-09-11: BMO Capital Markets Maintains Ariad Pharmaceuticals at Outperform, Raises PT from \$23 to \$31

Financial news for ARIA dated on 2012-09-10: UPDATE: Bank of America Upgrades Ariad Pharmaceuticals to Buy on Risk/Reward

Financial news for ARIA dated on 2012-09-10: Bank of America Upgrades Ariad Pharmaceuticals from Neutral to Buy, Raises PO from \$20 to \$26

Financial news for ARIA dated on 2012-09-06: Stifel Nicolaus Maintains Ariad Pharmaceuticals at Buy, Raises PT from \$20 to \$24

Financial news for ARIA dated on 2012-08-30: Ariad Pharma Says EU Regulator Agrees to Accelerated Assessment; Submits Marketing Authorization Application for Ponatinib

Financial news for ARIA dated on 2012-08-20: ARIAD Begins Phase 1/2 Trial of Ponatinib in Japan

Financial news for ARIA dated on 2012-08-09: Barclays Maintains Ariad Pharmaceuticals at Overweight, Raises PT from \$20 to \$25

Financial news for ARIA dated on 2012-08-03: UPDATE: Maxim Group Reiterates Buy Rating, Raises PT on Ariad Pharmaceuticals

Financial news for ARIA dated on 2012-08-03: Maxim Group Maintains Ariad Pharmaceuticals at Buy, Raises PT from \$20 to \$24

Financial news for ARIA dated on 2012-08-02: JP Morgan Maintains Ariad Pharmaceuticals at Overweight, Raises PT from \$18 to \$23

Financial news for ARIA dated on 2012-08-02: Jefferies & Company Maintains Ariad Pharmaceuticals at Buy, Raises PT from \$18 to \$21

Financial news for ARIA dated on 2012-08-02: Ariad Pharmaceuticals Reports Q2 EPS \$-0.31 vs \$-0.27 Est

Financial news for ARIA dated on 2012-07-31: UPDATE: Rodman & Renshaw Raises PT on Ariad Pharmaceuticals to \$26

Financial news for ARIA dated on 2012-07-30: Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration

Financial news for ARIA dated on 2012-07-27: ARIAD Initiates Phase 3 Ponatinib FDA Trial

Financial news for ARIA dated on 2012-07-27: ARIAD Initiates Phase 3 Ponatinib FDA Trial

Financial news for ARIA dated on 2012-07-27: ARIAD Announces Initiation of Randomized Phase 3 Trial of Ponatinib in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Financial news for ARIA dated on 2012-06-04: Ariad CEO Berger: 'We Are Fully Committed to Creating a Global Oncology Business'

Financial news for ARIA dated on 2012-06-04: Ariad CEO Berger: 'Very Easy for Patients to Live with the Drug'

Financial news for ARIA dated on 2012-06-04: Ariad CEO Berger: 'We Presented Compelling Clinical Data on CML Drug Ponatinib'

Financial news for ARIA dated on 2012-06-04: Jim Cramer Interviews CEO Harvey J. Berger of Ariad Pharmaceuticals on Mad Money

Financial news for ARIA dated on 2012-06-04: PREVIEW: Jim Cramer to Interview CEO of Ariad Pharmaceuticals on Mad Money

Financial news for ARIA dated on 2012-06-04: Option Alert: Ariad Pharmaceuticals August 12 Put; Block Trade: 3,000 Contracts; Currently \$15.58

Financial news for ARIA dated on 2012-06-04: ARIAD Announces Updated Data from Pivotal PACE Trial of Ponatinib

Financial news for ARIA dated on 2012-05-16: Stocks to Watch for Thursday, May 17

Financial news for ARIA dated on 2012-05-14: Watchlist for Tuesday, May 15

Financial news for ARIA dated on 2012-05-10: UPDATE: Jefferies Raises PT to \$18 on ARIAD Pharmaceuticals; Regulatory Catalysts

Financial news for ARIA dated on 2012-05-10: Jefferies & Company Maintains Ariad Pharmaceuticals at Buy, Raises PT from \$17 to \$18

Financial news for ARIA dated on 2012-05-09: Ariad Pharmaceuticals Reports Q1 EPS \$-0.35 vs \$-0.26 Est; Revenues \$81K vs \$300.00K Est

Financial news for ARIA dated on 2012-04-12: UBS Initiates Coverage on Ariad Pharmaceuticals at Buy, Announces PT of \$20

Financial news for ARIA dated on 2012-03-21: UPDATE: Stifel Nicolaus Cuts Target to \$18 on Ariad Pharmaceuticals

Financial news for ARIA dated on 2012-03-21: Morning Social Media Outlook for Wednesday March 21 (SABA, KKD, TRGT, ARIA)

Financial news for ARIA dated on 2012-03-21: Stifel Nicolaus Maintains Ariad Pharmaceuticals at Buy, Lowers PT from \$19 to \$18

Financial news for ARIA dated on 2012-03-21: UPDATE: Merck and ARIAD Pharmaceuticals Provide Update on FDA Advisory Committee Vote; Voted 13 To 1 Against The Use of Ridaforolimus

Financial news for ARIA dated on 2012-03-21: Oppenheimer: FDA AdCom Votes Against Approving Ridaforolimus

Financial news for ARIA dated on 2012-03-20: Ariad Pharmaceuticals Falls 5% on FDA Panel Vote

Financial news for ARIA dated on 2012-03-20: FDA Panel Votes 13-1 Against Recommending Taltorvic As Maintenance Treatment For Soft-tissue And Bone Sarcoma -Reuters

Financial news for ARIA dated on 2012-03-15: UPDATE: Stifel Nicolaus Initiates Buy, \$19 PT on Ariad Pharmaceuticals

Financial news for ARIA dated on 2012-03-15: Stifel Nicolaus Maintains Ariad Pharmaceuticals at Buy, Announces PT of \$19

Financial news for ARIA dated on 2012-03-12: Notable Put Options Activity in ARIAD Pharmaceuticals

Financial news for ARIA dated on 2012-03-12: Ariad Pharmaceuticals Trading 3.5% Higher on Heavy Volume; Currently at \$15.24

Financial news for ARIA dated on 2012-03-08: Bank of America: Closer Look at Ariad Pharmaceuticals' Inhibitor Landscape

Financial news for ARIA dated on 2012-02-29: UPDATE: Oppenheimer Ups PT to \$20 on Ariad Pharmaceuticals

Financial news for ARIA dated on 2012-02-29: Jefferies & Company Maintains Ariad Pharmaceuticals at Buy, Raises PT from \$16 to \$17

Financial news for ARIA dated on 2012-02-28: Rodman & Renshaw Maintains Market Perform, \$18 PT

Financial news for ARIA dated on 2012-02-28: Ariad Pharmaceuticals Reports Q4 EPS \$-0.38 vs \$-0.19 Est

Financial news for ARIA dated on 2012-02-16: Option Alert: Ariad Pharmaceuticals February 14 Call Block Trade, 3,000 Contracts

Financial news for ARIA dated on 2012-02-15: ARIAD Announces Issuance of Key U.S. Patent on Ponatinib

Financial news for ARIA dated on 2012-02-12: Weekly Traders Homework: The First Sign Of Weakness In 2012

Financial news for ARIA dated on 2012-02-06: Ariad Pharmaceuticals Hits 52-Week High of \$15.50

Financial news for ARIA dated on 2012-02-03: Ariad Pharmaceuticals Hits 52-Week High of \$15.44

Financial news for ARIA dated on 2012-02-02: Notable Put Options Activity in ARIAD Pharmaceuticals

Financial news for ARIA dated on 2012-02-02: Ariad Pharmaceuticals Hits 52-Week High of \$15.35

Financial news for ARIA dated on 2012-02-02: Option Alert: Ariad Pharmaceuticals August 9 Put; Block Trade, 4,950 Contracts

Financial news for ARIA dated on 2012-01-27: Ariad Pharmaceuticals Hits 52-Week High of \$15.15

Financial news for ARIA dated on 2012-01-25: Ariad Pharmaceuticals Hits 52-Week High of \$14.77

Financial news for ARIA dated on 2012-01-17: Ariad Pharmaceuticals Hits 52-Week High of \$14.61

Financial news for ARIA dated on 2012-01-15: Bullish setups that you should watch next week

Financial news for ARIA dated on 2012-01-13: Ariad Pharmaceuticals Hits 52-Week High of \$14.30

Financial news for ARIA dated on 2012-01-11: Ariad Pharmaceuticals Hits 52-Week High of \$14.07

Financial news for ARIA dated on 2012-01-11: Rodman & Renshaw Maintains Outperform, \$18 PT on Ariad Pharmaceuticals

Financial news for ARIA dated on 2012-01-09: Ariad Pharmaceuticals Hits 52-Week High of \$13.94

Financial news for ARIA dated on 2012-01-06: Ariad Pharmaceuticals Hits 52-Week High of \$13.51

Financial news for ARIA dated on 2012-01-04: Benzinga's Volume Gainers

Financial news for ARIA dated on 2012-01-03: ARIAD to Trade on the NASDAQ Global Select Market

Financial news for ARIA dated on 2011-12-27: Notable Put Options Activity on ARIAD Pharmaceuticals

Financial news for ARIA dated on 2011-12-27: Best Biotech Stocks of 2011

Financial news for ARIA dated on 2011-12-27: Rodman & Renshaw Raises PT on ARIAD Pharma to \$18

Financial news for ARIA dated on 2011-12-19: Notable Put Options Activity in ARIAD Pharmaceuticals

Financial news for ARIA dated on 2011-12-18: Weekly Homework: Are Bonds Trying To Tell Us Something? (w/ Economic Calendar & Stock Radar)

Financial news for ARIA dated on 2011-12-16: ARIAD Announces Underwriters' Exercise of Over-Allotment Option

Financial news for ARIA dated on 2011-12-15: ARIAD Announces Pricing of Public Offering of Common Stock at \$10.42 per Share

Financial news for ARIA dated on 2011-12-14: ARIAD Announces Proposed Public Offering of Common Stock

Financial news for ARIA dated on 2011-12-14: Ariad Pharma Files Automatic Mixed Securities Shelf

Financial news for ARIA dated on 2011-12-12: Bank of America Maintains Neutral, \$14 PT on Ariad Pharmaceuticals

Financial news for ARIA dated on 2011-12-12: Benzinga's Top Pre-Market Gainers

Financial news for ARIA dated on 2011-12-12: Jefferies Maintains Buy Rating on Ariad Pharma

Financial news for ARIA dated on 2011-12-12: ARIAD Announces Preliminary Data from Pivotal Pace Trial of Ponatinib, Its Investigational pan-BCR-ABL Inhibitor

Financial news for ARIA dated on 2011-12-12: J.P. Morgan Maintains Overweight Rating on Ariad Pharmaceuticals

Financial news for ARIA dated on 2011-12-11: Weekly Homework: In Search Of The Santa Claus Rally (w/ Economic Calendar & Stock Radar)

Financial news for ARIA dated on 2011-12-09: Five Biotech Stocks to Watch Going into Big Doctors' Meeting

Financial news for ARIA dated on 2011-12-02: Jefferies Maintains Buy Rating and \$16 PT on ARIAD Pharmaceuticals

Financial news for ARIA dated on 2011-11-18: FDA Approves Erwinaze To Treat A Form Of Leukemia

Financial news for ARIA dated on 2011-11-17: ARIAD Announces Interim Safety and Efficacy Data from Pivotal Ponatinib PACE Trial to Be Presented

Financial news for ARIA dated on 2011-11-07: Hearing BMO Capital Reiterates \$18 PT on Ariad Pharmaceuticals

Financial news for ARIA dated on 2011-11-07: Notable Put Options Activity in ARIAD Pharmaceuticals

Financial news for ARIA dated on 2011-11-04: Rodman & Renshaw Maintain Market Outperform Rating and \$15 PT on ARIAD Pharmaceuticals

Financial news for ARIA dated on 2011-11-01: Rodman & Renshaw Maintain Market Outperform Rating and \$15 PT on ARIAD Pharmaceuticals

Financial news for ARIA dated on 2011-10-14: Rodman & Renshaw Initiates ARIAD Pharmaceuticals at Market Outperform, \$15 PT

Financial news for ARIA dated on 2011-10-07: Six Stocks Under \$10 Lottery Specials

Financial news for ARIA dated on 2011-10-05: Notable Call Options Activity in ARIAD Pharmaceuticals

Financial news for ARIA dated on 2011-10-05: FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor

Financial news for ARIA dated on 2011-09-26: BofA/ML Reiterates Neutral Rating on Ariad Pharmaceuticals

Financial news for ARIA dated on 2011-09-26: ARIAD Announces Long-Term Follow Up of Patients with Drug-Resistant CML Treated with Ponatinib in Phase 1 Trial

Financial news for ARIA dated on 2011-09-21: ARIAD Announces Start of Enrollment in Phase 1/2 Clinical Trial of Oral AP26113, an Investigational Dual Inhibitor of ALK and EGFR in Patients with Lung Cancer

Financial news for ARIA dated on 2011-09-14: UPDATE: Oppenheimer Raises Price Target On Ariad Pharmaceuticals To \$17

Financial news for ARIA dated on 2011-08-29: Morning Gainers; Dresser-Rand Group up 11%

Financial news for ARIA dated on 2011-08-18: Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus

Financial news for ARIA dated on 2011-08-18: Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus

Financial news for ARIA dated on 2011-08-16: Mad Money Lightning Round: Cramer Likes Starbucks, BJ's Restaurants

Financial news for ARIA dated on 2011-08-02: Ariad Pharmaceuticals Reports Q2 EPS \$(0.36) vs \$(0.18) Est

Financial news for ARIA dated on 2011-08-01: ARIAD Announces That Merck Has Submitted for Approval of Ridaforolimus, an Investigational mTOR Inhibitor, in the EU

Financial news for ARIA dated on 2011-08-01: ARIAD Announces That Its Partner, Merck, Has Submitted for Approval of Ridaforolimus, an Investigational mTOR Inhibitor, in the European Union

Financial news for ARIA dated on 2011-07-25: Benzinga's Top ETF Decliners, July 25th (SOXL, URTY, DRN, XBI)

Financial news for ARIA dated on 2011-07-21: 15 Lottery Specials Under \$10

Financial news for ARIA dated on 2011-07-20: Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows

Financial news for ARIA dated on 2011-07-19: Bank of America Initiates Ariad Pharmaceuticals At Neutral, \$14 PO

Financial news for ARIA dated on 2011-07-17: Stocks to Watch for Monday 7/18/2011: Fresh 52 Week Highs and Lows

Financial news for ARIA dated on 2011-07-11: Stocks to Watch for Tuesday 07/12/11: Fresh 52 Week Highs and Lows

Financial news for ARIA dated on 2011-07-11: NASDAQ Stocks Hitting 52-Week Highs

Financial news for ARIA dated on 2011-07-10: Stocks to Watch for Monday 07/11/11: Fresh 52 Week Highs and Lows

Financial news for ARIA dated on 2011-06-29: Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows

Financial news for ARIA dated on 2011-06-28: Options Brief: ARIAD Pharmaceuticals, Inc.

Financial news for ARIA dated on 2011-06-28: Tuesday's Put/Call Ratio Leaders

Financial news for ARIA dated on 2011-06-28: Stocks to Watch for 6/28/11: Fresh 52 Week Highs and Lows

Financial news for ARIA dated on 2011-06-24: Stocks to Watch for 6/24/11: Fresh 52 Week Highs and Lows

Financial news for ARIA dated on 2011-06-22: Stocks to Watch for 6/22/11: Fresh 52 Week Highs and Lows

Financial news for ARIA dated on 2011-06-20: Trade Setups For 6/21

Financial news for ARIA dated on 2011-06-20: J.P. Morgan Reiterates Overweight Rating On Ariad Pharmaceuticals

Financial news for ARIA dated on 2011-06-20: JP Morgan Raises PT On Ariad Pharmaceuticals To \$13

Financial news for ARIA dated on 2011-06-16: ARIAD Announces Broader Profile of Its Investigational Lung Cancer Drug Candidate Showing Dual Inhibition of ALK and EGFR

Financial news for ARIA dated on 2011-06-10: Stocks to Watch 6/10/11: Fresh 52-Week Highs and Lows

Financial news for ARIA dated on 2011-06-07: Top Percentage Gainers and Losers as of 2pm 06/07/11

Financial news for ARIA dated on 2011-06-07: Top Percentage Gainers and Losers as of 12pm 06/07/11

Financial news for ARIA dated on 2011-06-07: Ariad Pharmaceuticals Spiking over 10% on the Session

Financial news for ARIA dated on 2011-06-07: Jefferies Provides Color on Ariad Pharmaceuticals, Buy

Financial news for ARIA dated on 2011-06-07: J.P. Morgan Maintains Rating, PT Following Presentation By ARIA

Financial news for ARIA dated on 2011-06-06: UPDATE: Ariad Pharmaceuticals CEO: Clearly Not For Sale

Financial news for ARIA dated on 2011-06-06: UPDATE: Ariad Pharmaceuticals CEO: Cancer Drug Spending Could Rise 15%/Year Through 2013

Financial news for ARIA dated on 2011-06-06: UPDATE: Ariad Pharmaceuticals CEO Currently Speaking on CNBC: Deal with Merck Gave it Resources

Financial news for ARIA dated on 2011-06-06: PREVIEW: Ariad Pharmaceuticals CEO Coming Up on CNBC Shortly

Financial news for ARIA dated on 2011-06-06: Jefferies Provides Color on Ariad Pharmaceuticals, Buy

Financial news for ARIA dated on 2011-06-06: Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting

Financial news for ARIA dated on 2011-06-03: ARIAD Announces Initial Clinical Data on Ponatinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Financial news for ARIA dated on 2011-05-25: Brean Murray Raises PT on Ariad Pharmaceuticals To \$11

Financial news for ARIA dated on 2011-05-24: Mad Money Lightning Round OT: Cramer Likes BYD (DF, BYD, ARIA)

Financial news for ARIA dated on 2011-05-10: Calls Purchased on ARIAD Pharmaceuticals (ARIA)

Financial news for ARIA dated on 2011-04-20: Head and Shoulders 04-20-2011

Financial news for ARIA dated on 2011-04-20: Growthflation 04-20-2011

Financial news for ARIA dated on 2011-04-20: REGENX BioSciences Licenses ARGENT Gene Regulation Technology From ARIAD Pharmaceuticals, Inc.

Financial news for ARIA dated on 2011-04-20: ARIAD Announces Three Exclusive Out-License Agreements to Develop and Commercialize Its ARGENT Cell-Signaling Regulation Technology

Financial news for ARIA dated on 2011-04-05: ARIAD Presents New Preclinical Data on Ponatinib in Solid Tumors, Demonstrating Inhibition of All FGF Receptor Kinases

Financial news for ARIA dated on 2011-03-30: Mad Money Lightning Round OT: Cramer Likes NEOG And ARIA

Financial news for ARIA dated on 2011-03-29: Ariad Pharma Ticks Lower After CEO Comments That Company Is Not Up For Sale (ARIA)

Financial news for ARIA dated on 2011-03-29: Stocks on the Move(ARIA) \$7.32 New Year High

Financial news for ARIA dated on 2011-03-28: ARIAD And MolecularMD Announce Collaboration for a Companion Diagnostic Test for The T315I BCR-ABL Mutation in Patients With CML

Financial news for ARIA dated on 2011-03-17: ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval

Financial news for ARIA dated on 2011-01-19: Benzinga's After Hours Gainers (EBAY, ARIA, VC)

Financial news for ARIA dated on 2011-01-19: Radian, Depomed: Small-Cap Losers

Financial news for ARIA dated on 2011-01-19: Ariad Scores With SUCCEED - Analyst Blog

Financial news for ARIA dated on 2011-01-19: Ariad Scores With SUCCEED - Analyst Blog

Financial news for ARIA dated on 2011-01-19: Stock Market News for Jan 19, 2011 - Market News

Financial news for ARIA dated on 2011-01-19: Stock Market News for Jan 19, 2011 - Market News

Financial news for ARIA dated on 2011-01-18: Ariad Pharmaceuticals Skyrocketing (ARIA)

Financial news for ARIA dated on 2011-01-18: Sterling, Ener1: Small-Cap Winners

Financial news for ARIA dated on 2011-01-18: Morning Market Movers (DTLK, PNBC, ARIA, SBIB)

Financial news for ARIA dated on 2011-01-18: Ariad Pharmaceuticals Announces Its Phase 3 SUCCEED Trial Hits Primary Endpoint

Financial news for ARIA dated on 2011-01-18: Benzinga's Top Pre-Market NASDAQ Gainers (ARIA, SBIB, KUTV, VOD)

Financial news for ARIA dated on 2011-01-18: Ariad Sarcoma Drug Delays Progression

Financial news for ARIA dated on 2011-01-05: Jefferies Raises PT On Ariad Pharmaceuticals

Financial news for ARIA dated on 2010-12-20: Top Stock Picks Under \$5 for 2011

Financial news for ARIA dated on 2010-12-13: Monday's Put/Call Ratio Leaders (FLIR, YGE, FAST, TIE, ARIA)

Financial news for ARIA dated on 2010-12-08: Biotech's Brighter Corners

Financial news for ARIA dated on 2010-12-06: 10 Lottery Stocks Under \$10

Financial news for ARIA dated on 2010-12-06: Ponatinib, A Key Driver For ARIAD Pharmaceuticals, Jefferies Reports

Financial news for ARIA dated on 2010-11-29: Options Brief: ARIAD Pharmaceuticals (ARIA)

Financial news for ARIA dated on 2010-11-29: Lessons From A Losing Biotech Portfolio

Financial news for ARIA dated on 2010-10-26: ARIAD Prices Public Offering at \$3.70 per Share

Financial news for ARIA dated on 2010-10-26: Benzinga's Top Pre-Market NASDAQ Losers (ZRRN, TLAB, ARIA, ARMH)

Financial news for ARIA dated on 2010-10-25: Offering: Ariad Pharmaceuticals, Inc to offer 16 million shares.

Financial news for ARIA dated on 2010-10-25: Ariad Pharmaceuticals Jumping (ARIA)

Financial news for ARIA dated on 2010-10-19: Bulls Bet ARIAD Pharma Continues To Run (ARIA)

Financial news for ARIA dated on 2010-10-08: Friday's Put/Call Ratio Leaders (GGB, ARIA, RYL, UBS, CIM)

Financial news for ARIA dated on 2010-09-14: Jefferies Reiterates Buy Rating on ARIAD Pharma (ARIA)

Financial news for ARIA dated on 2010-09-09: Top 10 'Buy'-Rated Stocks Under \$5

Financial news for ARIA dated on 2010-07-14: 10 Firms Expecting Clinical Trial Results

Financial news for ARIA dated on 2010-06-29: Benzinga's Top Pre-Market Losers (MU, OREX, ARIA, SOLF)

Financial news for ARIA dated on 2010-06-08: Ariad Pharmaceuticals' New Drug Shows Promise, Says JP Morgan

Financial news for ARIA dated on 2010-06-07: Downside Purchased on Ariad Pharma (ARIA)

Financial news for ARIA dated on 2010-05-13: Ariad Pharmaceuticals (ARIA) Reports 1Q Financials, Buy Reiterated at Brean Murray Carrett & Co.

Financial news for ARIA dated on 2010-05-05: Merck And Ariad Re-Write Ridaforolimus Contract (MRK, ARIA)

Financial news for ARIA dated on 2010-05-05: Benzinga's Top Pre-Market Gainers (AMMD, HNSN, ACAS, ARIA, ERTS)

Financial news for ARIA dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for ARIA dated on 2010-03-18: Benzinga's Top Downgrades (ASTI , WAB, ARIA, WNS, WNI)

Financial news for ARIA dated on 2010-03-04: Curious Positioning in Ariad

Financial news for ARIA dated on 2010-03-01: Benzinga's Top Pre-Market Gainers (OSIP, BIOD, ARIA, RMTI, DISH)

Financial news for ARIA dated on 2010-01-11: Benzinga's Top Pre- Market Losers (ASBC, MNKD, HOGS, AIXG, ARIA, ICXT)

Financial news for ARIA dated on 2009-12-08: Barclays Continue With Their Overweight Call For ARIAD Pharmaceuticals (ARIA)

Financial news for ARIA dated on 2009-12-08: Benzinga's Top Pre- Market Gainers (ZILG, YONG, GERN, ARIA, XLNX)

Financial news for ARIA dated on 2009-11-09: Benzinga's Updates (FUQI, ARIA, RCKY, STAA)

Financial news for ARIA dated on 2009-11-09: JPMorgan Upgrades Ariad Pharmaceuticals, Inc. To Overweight